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Zusammenfassung: 
Das maligne Pleuramesotheliom (MPM) ist eine aggressive, Asbest-assoziierte Krebsart mit 
einer generell sehr schlechten Prognose. Bis heute gibt es nur wenige therapeutische 
Optionen, da Chemo- und Radiotherapie häufig nicht anschlagen. Fibroblasten 
Wachstumsfaktoren (FGF) und deren Rezeptoren (FGFR) regulieren Wachstum, 
Wanderungsverhalten und Überleben von Zellen und sind an wichtigen physiologischen 
Prozessen aber auch an der Entstehung und dem Fortschreiten von Krebs beteiligt. Der FGF 
Signalweg wurde bereits als potentielles Target für neuartige Therapien in diverse 
Krebsarten in Erwägung gezogen, aber bisher noch nicht  für das maligne 
Pleuramesotheliom. 
Ziele: Daher war das Ziel dieser Studie die Evaluierung des FGF/FGFR Signalsystems als 
mögliches „Therapietarget“ auch für MPM durch eine Analyse der FGF und FGFR Expression, 
sowie des Einflusses einer Blockade des FGFR1 auf Erscheinungsbild, Wachstum, 
Spheroidbildung, intrazelluläre Signalkaskaden sowie Sensitivität gegenüber Chemo- und 
Radiotherapie auf MPM Zellen. 
Methoden: Die Expression aller vier FGFRs samt Isoformen und der 22 FGFs wurde mittels 
konventioneller PCR, qRT-PCR, Immunfluoreszenz, genetischen Reporterkonstrukten in MPM 
Zellinien (n=9) und teilweise durch immunhistochemische Färbungen in 
Tumorgewebeproben (N=60) nachgewiesen. Zur Stimulierung beziehungsweise Blockierung 
des FGF Signalwegs wurden rekombinantes FGF2, die synthetischen Inhibitoren SU5402 und 
PD166866 sowie ein dominant-negativer FGFR1-Adenovirus verwendet. Zellwachstum und 
Wanderung wurde durch MTT, Clonogenic, Platypus und Transwell Assays  ermittelt 
beziehungsweise durch Färbung mit Hoechst/PI und mikroskopische Betrachtung. 
Änderungen in intrazellulären Signalwegen wurden mittels Western Blot Analyse dargestellt. 
Resultate: Die Expressionsanalyse ergab eine starke Überexpression des FGFR1 im Bezug auf 
die anderen Rezeptoren und die Kontrollzelllinie, sowie eine hohe Expression von FGF2 und 
FGF18, sowohl in den Zelllinien als auch in Tumorgewebeproben. Die Blockierung des FGFR1 
durch spezifische Inhibitoren sowie ein Adenoviruskonstrukt führte zu beträchtlich 
vermindertem  Zellwachstum, Stimulation mit FGF2 hingegen zu einer Erhöhung sowie zu 
drastischen morphologischen Änderungen. Ähnliche Effekte wurden auch im Bezug auf das 
Wanderungsverhalten von MPM Zellen beobachtet, begleitet von Änderungen in 
intrazellulären Signaltransduktionskaskaden. Weiters resultierte die Inhibierung des FGFR1 
in stark verminderter Spheroidbildung, das Weglassen von FGF2 hingegen zu weniger 
dramatischen Effekten. Kombination von FGFR Inhibierung mit herkömmlicher Chemo-und 
Radiotherapie führte in den meisten Fällen zu einer Verstärkung der Wirkung. 
Schlussfolgerung: Unsere Daten zeigen, dass der FGF Signalweg in Mesotheliomzellen eine 
wichtige Rolle für Wachstum, Überleben, Wanderungsverhalten sowie Chemo-und 
Strahlenresistenz spielt und es daher sinnvoll scheint, die Blockierung dieser Signale für 
potenzielle neue MPM Therapien weiter zu untersuchen. 
 Abstract:  
Malignant pleural mesothelioma (MPM) is a highly aggressive asbestos-related malignancy 
characterized by frequent resistance to chemo- and radiotherapy with poor outcome and 
limited therapeutic options. Fibroblast growth factors (FGF) and their receptors (FGFR) 
comprise a signaling system that is involved in essential physiologic processes, but is also 
critically involved in tumor development and progression by regulating cell growth, 
migration and survival. The FGFR signaling pathway has been identified as potential therapy 
target in several tumor types but has not been systematically investigated in MPM so far.  
Objectives: The purpose of this study was to provide a systematic analysis of the expressed 
FGF as well as FGFR molecules in MPM and to investigate the impact of blocking FGFR-
mediated signals on MPM cell morphology, growth, spheroid formation, migration, invasion, 
signaling pathways and sensitivity to irradiation and chemotherapeutic agents to evaluate 
the FGF/FGFR axis as potential therapy target in MPM.  
Methods: Expression of all four FGFRs including different isoforms and 22 FGFs was analyzed 
in a panel of MPM cell lines (n=9) via conventional PCR, qRT-PCR, immunoflourescence and 
genetic reporter constructs as well as by immunohistochemistry in tissue samples (n=60). 
The FGFR pathway was stimulated/blocked using recombinant FGF2, a dominant-negative 
FGFR1 adenoviral construct and the specific small-molecule FGFR inhibitors SU5402 and 
PD166866. Cell growth, spheroid formation, migration and invasion were assessed by MTT, 
clonogenic, platypus and transwell assay as well as Hoechst/PI staining and microscopic 
examination. Changes in FGFR-mediated signaling were evaluated by western blot analysis.  
Results: Expression analysis revealed high overexpression of FGFR1 in all investigated MPM 
cell lines compared to the other receptors and the control cell line. Concerning the 
expression of the ligands, high transcript levels of FGF2 and FGF18 were detected, whereas 
other FGFs were expressed at more moderate levels. Immunohistochemistry of human 
tissue samples derived from surgery also showed an overexpression of activated FGFR1, 
FGF2 and FGF18 compared to the surrounding tissue. Inhibition of FGFR1 by the specific 
Inhibitor PD166866 led to decreased proliferation, migration and invasion in all cell lines 
tested, which was further confirmed in selected cases by adenoviral expression of dnFGFR1. 
In contrast, stimulation with FGF2 showed remarkably increased migration and dramatic 
changes in morphology accompanied by distinct changes in cellular signal transduction 
pathways. Inhibition of FGFR signals also markedly reduced spheroid formation ability of 
MPM cell lines whereas FGF-free conditions showed a more moderate reduction. 
Combination of FGFR inhibition with irradiation or currently used chemotherapeutic agents 
e.g. cisplatin led to increased efficacy with respect to cell viability. 
Conclusion: Our data suggest that FGFR-mediated signals are important for proliferation, 
survival, migration, chemo- and radioresistance of mesothelioma cells and their inhibition 
should be further evaluated as a potential new treatment strategy in MPM. 
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1. INTRODUCTION: 
 
1.1. Fibroblast Growth Factors and their Receptors: 
 
1.1.1. Evolution, structural and functional properties of FGFs and FGFRs: 
 
The FGF/FGFR gene family: 
Fibroblast Growth Factors (FGF) and their specific receptors (FGFR) comprise a cell signaling 
pathway that is conserved throughout metazoan evolution (Itoh and Ornitz 2004). FGFs are 
polypeptides, which specifically bind and activate their receptors, phospho-tyrosine-kinases 
that are located on the cell membrane. FGFR activation further activates a set of intracellular 
signal transduction cascades, which have been shown to be essential for embryonic 
development, angiogenesis, wound healing and also play a notable role in tumor growth 
(Powers, McLeskey et al. 2000). 
Genes encoding FGFs and FGFRs have been identified in multicellular organisms, ranging 
from nematodes (C. elegans) and insects (D. melanogaster) to vertebrates such as the 
zebrafish (D. rerio),  the mouse (M. musculus) or the human (H. sapiens), but not in 
unicellular organisms like bacteria (E. coli) and yeast (S. cerevisiae) (Itoh and Ornitz 2004). 
Across metazoan species, most orthologous FGF proteins are highly conserved and share at 
least 90% amino acid sequence identity (Ornitz and Itoh 2001). 
The 22 FGF genes are scattered throughout the genome and several of them are clustered. 
These locations indicate that the FGF family was generated by gene and chromosomal 
duplication and also by translocation during evolution. For the FGF receptors, four functional 
genes have been identified, also distributed on different chromosomes in the genome, 
indicating that the FGF receptors probably also derived from one ancestral gene by gene or 
genome duplication (Itoh and Ornitz 2004). The use of tissue specific alternative splicing 
guarantees the expression of a variety of different receptor protein isoforms, increasing the 
functional diversity of FGF receptors (Ornitz and Itoh 2001).  
 
Fibroblast Growth Factors: 
Fibroblast growth factors are small proteins of 150-300 amino acids that range from 17 to 34 
kDa in molecular weight (Ornitz and Itoh 2001). Though they have many different features, 
all FGFs have a central core region of 120-130 amino acids that is highly homologous 
between different family members.  
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This central core consists of 12 antiparallel β-strands and contains heparin and heparin-like 
glycosaminoglycan (HLGAG) binding sites and also FGF receptor interaction regions.  
The cylindrical barrel, formed by the β-strands of the core region, is closed by the N- and C-
terminal tails that vary in sequence and account for the biological and functional differences 
of the ligands (Powers, McLeskey et al. 2000; Beenken and Mohammadi 2009). 
In mice and humans, 23 fibroblast growth factors have been identified, but FGF15 is seen as 
the mouse ortholog of human FGF19. Phylogenetic analyses arrange the 22 human FGFs into 
seven subfamilies, based on increased sequence similarity, as well as biochemical and 
developmental properties. The evolutionary relationships between the genes are shown in 
Figure 1. Branch lengths are proportional to the evolutionary distance between different 
genes (Itoh and Ornitz 2004). 
FGFs are classically considered as paracrine factors, 
except the members of the hormone-like FGF19 
subfamily (FGF19, FGF21, and FGF23). Those factors 
function in an endocrine manner and regulate 
cholesterol, glucose, vitamin D and phosphate 
homeostasis (Heinzle, Sutterluty et al. 2011). 
Most of the FGFs encode a signal peptide that mediates 
secretion through the ER-Golgi pathway, with the 
exception of two FGF subfamilies. The FGF9 subfamily 
members (FGF9, FGF16, and FGF20) are also secreted, 
though they lack a signal peptide. Members of the FGF1 
subfamily (FGF1, FGF2) also lack signal peptides. They 
are released from damaged cells or independent from 
the ER-Golgi secretion pathway. Some isoforms of FGF2 
also contain a nuclear localization sequence and can be 
found in association with the nucleus. FGF22 remains 
attached to the cell surface (Bugler et al. 1991; Powers, 
McLeskey et al. 2000).  
The members of the FGF11 subfamily (FGF11-14) are generally not considered as genuine 
members of the FGF gene family and known as fibroblast homology factors (FHFs). Though 
they show high sequence identity to the FGFs, FHFs do not bind and activate FGF receptors. 
Their targets are the intracellular domains of voltage-gated sodium channels (Beenken and 
Mohammadi 2009).  
As briefly mentioned before, a defining feature of members of the FGF family is their strong 
affinity for heparin and HLGAGs (Burgess and Maciag 1989). These interactions comprise two 
major functions. On the one hand they stabilize the FGFs against thermal denaturation and 
prevent proteolytic degradation. 
Figure 1: 
Evolutionary relationships within the human 
fibroblast growth factor (FGF) gene family 
(Itoh and Ornitz 2004). 
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The second physiologically relevant consequence is the creation of a local reservoir of 
growth factors by limiting the diffusion radius into the ECM of the connective tissue. This 
large supply of FGFs can then, if required, be released from such microenvironmental stores 
by the action of specific FGF-binding proteins (Powers, McLeskey et al. 2000; Ornitz and Itoh 
2001; Heinzle, Sutterluty et al. 2011). 
Additionally, heparin and HLGAGs facilitate FGF-FGFR dimerization by binding both the 
ligand and the receptor, thereby stabilizing the protein-protein contact and increasing the 
half life of the complex (Beenken and Mohammadi 2009). Otherwise, HLGAGs have been 
shown to prevent FGFR dimerization and activation in absence of FGFs (Kan et al. 1996). 
 
Fibroblast Growth Factor Receptors: 
High affinity FGF receptors are a subfamily of the receptor tyrosine kinases (RTK) and consist 
of about 800 amino acids, containing a highly conserved split intracellular kinase domain, a 
single-pass transmembrane domain and an extracellular ligand binding domain that contains 
two or three immunoglobulin (Ig)-like domains, a heparin binding site and the acid box, an 
acidic, serine-rich sequence between IgI and IgII (Johnson et al. 1991). 
To increase the functional diversity of the FGF receptors, several isoforms are generated, as 
in FGFR1-3, the IgI domain and/or the acid box can be removed by exon skipping. The 
introduction of early stop codons may result in secreted receptors that do not possess a 
transmembrane domain (Johnson and Williams 1993). Additionally, alternative splicing of 
the IgIII loop of FGFR1-3 creates the IIIb and IIIc variants, that have distinct binding 
specificities and are predominantly expressed in epithelial and mesenchymal tissues, 
respectively (Johnson, Lu et al. 1991). FGFR4 is generally excluded from these processes, but 
contains a well studied germline single nucleotide polymorphism (SNP) that causes a glycine 
to arginine substitution in position 388 (G388R) of the transmembrane domain, affecting 
receptor stability and also playing a role in cancer progression (Bange et al. 2002). A 
schematic illustration of the protein structure of the major FGF receptor variants, including 
the IIIb/IIIc splice variants is shown in Figure 2 below. 
 
 
 
 
 
 
Figure 2: 
Protein structure of possible FGFR splice variants, including the different IgIIIb/IIIc  variants 
(Powers et al. 2000). 
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1.1.2.  FGF Receptor activation and downstream signaling: 
It is a general feature of receptor tyrosine kinases to transmit extracellular signals to a 
variety of intracellular signal transduction cascades through tyrosine phosphorylation, and 
this is also true for the FGF receptors. Fibroblast growth factors bind specifically to the 
different splice variants of their high-affinity receptors. The individual FGFs widely vary in 
their receptor specificities. Several FGFs can only bind to one or two receptors, whereas 
FGF1, for instance, can activate almost all receptor variants, as shown in Table 1 below 
(Heinzle, Sutterluty et al. 2011).  
Table 1: 
Different splice variants of FGF receptors and their ligands (Heinzle, Sutterluty et al. 2011).  
 
Ligand binding is followed by receptor activation, meaning dimerization and phosphorylation 
of specific tyrosine residues on the cytoplasmatic tails. Thus, a functional FGF-FGFR dimer 
consists of two 1:1:1 FGF-FGFR-HLGAG complexes that are arranged in a symmetrical dimer, 
as indicated in Figure 3 (Schlessinger et al. 2000).  
 
 
 
 
 
 
 
 
 
 
 
Figure 3: 
Protein structure of the FGF-FGFR complex, including the different 
IgIIIb/IIIc splice variants (Heinzle et al. 2011). 
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Consequently, after dimerization, receptors become capable of phosphorylating themselves 
and their dimerization partner, which can be seen as auto- and transphosphorylation, 
respectively (Lemmon and Schlessinger 1994). The ability to transphosphorylate other 
receptors extends to both, FGFR homo- and heterodimers, allowing for additional 
complexity in FGF signaling (Bellot et al. 1991; Powers, McLeskey et al. 2000). Then, the 
phosphorylated tyrosine residues recruit other signaling molecules which can either become 
phosphorylated themselves by the receptor kinase or function as adaptors recruiting further 
target proteins by their own specific binding sites and therefore propagate the signal 
through many possible intracellular transduction pathways. Generally, this propagation of 
signals is achieved by induction of a conformational change resulting in activation of catalytic 
sites of the respective protein (Pawson 1995). Figure 4 shows the major downstream targets 
and signaling pathways of FGFRs.  
 
 
 
 
 
 
 
 
 
 
 
 
 
The primary FGF receptor substrate is FRS2, which mainly activates the ras-pathway. Ras 
then further activates the PI3K/Akt pathway and the MAPK pathway, which both drive cell 
proliferation and survival (Eswarakumar et al. 2005). Another substrate of FGFRs is PLCγ that 
also upregulates MAPK signaling via PKC. Additionally, activation of STAT signaling has been 
observed in tumor cells (Klint and Claesson-Welsh 1999). FGFRs also interact with cell 
adhesion molecules such as N-cadherin and N-CAM, which have been found to recruit and 
activate src-kinase and promote, for example, cell migration (Cavallaro et al. 2001).  
Figure 4: 
Illustration of target proteins and downstream signaling cascades associated with FGF receptors 
(Heinzle, Sutterluty et al. 2011). 
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Since FGFR signaling comprises essential roles concerning cell migration, proliferation and 
survival, strict and accurate regulation is crucial for an intact and functional signaling system. 
Consequently, concurrently to FGFR signaling, auto-regulatory negative feedback loops are 
activated, controlling intensity and duration of the signal (Dikic and Giordano 2003). One 
major group of such endogenous inhibitors counteracting FGF-induced processes comprises 
the Sprouty proteins (Hacohen et al. 1998). 
 
1.1.3. Physiological roles of FGF signaling: 
Fibroblast growth factors have been shown to play important roles in several biological 
processes, during embryonic development as well as in adult organisms, which has been 
solidly proven by extensive studies in genetic mouse models and human pathologies. Several 
FGFs induce cell division of embryonic and extraembryonic cells as early as the fifth cell 
division (Chai et al. 1998) and play an essential role in embryonic stem cell regulation and 
gastrulation, where the three germ layers are formed (Powers, McLeskey et al. 2000). 
Additionally, FGF-mediated tissue cross talk between epithelial and mesenchymal cells is an 
essential feature in embryogenesis (Tickle and Munsterberg 2001). Organogenesis is also 
driven by FGFs, particularly development of the nervous system, the brain and the lung 
(Crossley et al. 1996; Sekine et al. 1999) but most importantly, limb development and limb 
bud induction (Cohn et al. 1995).  
Thalidomide, better known as Contergan, is one prominent example for this process. The 
drug inhibits angiogenesis and also interferes with FGF-mediated signaling by inhibiting FGF2 
and was originally used as a sedative, but then turned out to cause limb defects in babies 
(Powers, McLeskey et al. 2000). 
In humans, defects or alterations of FGFs or FGFRs result in a wide variety of diseases, for 
example skeletal and growth defects such as craniosynostosis and dwarfing syndromes 
(Beenken and Mohammadi 2009), a hereditary form of rickets (Shimada et al. 2001), but also 
Parkinson disease (van der Walt et al. 2004). 
Another significant feature of FGFs is the promotion of angiogenesis which further plays a 
role in wound healing and tissue repair (Su et al. 2008). FGFs are released into the ECM from 
their HLGAG-bound microenvironmental stores from mechanically wounded endothelial 
cells and fibroblasts. These factors further can induce the migration of inflammatory cells by, 
for example, stimulating the production of platelets and IL2 (Byrd et al. 1999). During the 
repair phase of wound healing, FGFs have proliferative effects on endothelial cells and 
fibroblasts and also facilitate endothelial cell migration by regulation of cell adhesion 
molecules and proteolysis (Besser et al. 1995; Gualandris and Presta 1995). Finally, as 
mentioned before, angiogenesis and neovascularization, the sprouting of new vessels, is also 
stimulated by fibroblast growth factors (Su, Mendoza et al. 2008).  
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The hormone-like FGFs (FGF19 subfamily) circulate systemically and achieve different 
metabolic control functions such as glucose uptake (Kharitonenkov et al. 2005), energy- and 
lipid metabolism (Itoh 2010). 
 
1.2. Fibroblast Growth Factors and Cancer: 
 
1.2.1. Cancer – an overview: 
Every existence is based on a controlled equilibrium between living and death. In multi-
cellular organisms every single cell has its own specific role to achieve, and homeostasis and 
maintenance of normal tissue architecture and function is only possible when features like 
cell growth, cell differentiation and cell death are well balanced. Disruption of this 
equilibrium may lead to uncontrolled and increased cell growth and further spreading and 
settling into other tissues. This describes the main characteristics of the second most 
common deadly disease in industrialized countries, cancer. 
The human organism features a variety of complex mechanisms maintaining homeostasis.  
Cell fates are determined and regulated by a multitude of intra- and extracellular signaling 
pathways and further controlled by autonomous feedback mechanisms, securing that 
aberrant cells are stopped and do not harm the organism. In the last decades, extensive 
research identified changes in the cellular genome leading to consistent dysfunction of these 
protective mechanisms, providing the possibility for the development of cancer.  
The majority of the somatic mutations leading to progressive tumor growth arises 
sporadically and is caused by environmental influences such as physical and chemical 
mutagens, carcinogenic substances and certain viruses. Some prominent examples are 
tobacco smoke, UV light and the human papilloma virus (HPV), leading to lung cancer, 
melanoma and cervical cancer, respectively. Once harboring mutations, potential tumor cells 
can be further promoted by hormones and certain lifestyle factors such as diet, alcohol 
consumption and obesity, related with for example gut, liver and colon cancers.   
However, susceptibility to cancer can also be inherited. These changes in the genome usually 
affect tumor-suppressor and mismatch-repair genes, causing a general genomic instability. 
So called high-risk mutations have been found to predispose to several cancer types such as 
breast, colon and ovarian cancer, retinoblastoma and hematologic malignancies such as 
leukemias and lymphomas (Vineis et al. 2010).  
Progression from aberrant cells to malignancy is the result of the accumulation of these 
genetic aberrations during a lifetime. Thus, a very prominent factor determining the chance 
to develop cancer is age, as shown in Figure 5.  
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Molecular mechanisms of cancer development: 
Normally, more than one somatic mutation is required to 
trigger tumor progression, and cancer does not develop 
from one day to another. The change from a normal cell 
into a malignant tumor cell requires multiple steps and 
lasts years. This process is described by a simplified three-
stage-model (De Braekeleer 1984) in Figure 6.  
The first step, initiation, is mostly caused by mutagens and 
involves a genomic change resulting in some kind of 
advantage for the cell, for example avoiding apoptosis. 
During tumor promotion the cell gains more and more 
benefits and starts to proliferate excessively, forming a so 
called benign tumor, which is not capable to invade the 
surrounding tissue. Accumulation of further mutations 
finally leads to the third step, tumor progression. The 
malignant cells have now the potential to infiltrate the 
surrounding tissue, to move through the lymphatic or 
hematogenic system and to survive and proliferate in 
other parts of the body by forming metastases. 
 
Figure 5: 
Age-specific average number of new cancer cases per year and incidence rates including all 
cancers except non-melanoma skin cancers for males and females in the UK (Cancer 
Research UK). 
Figure 6: 
Simplified illustration of the three-stage 
model of carcinogenesis (www.dkfz.de, 
accessed 05/2011). 
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Most genes that are affected during tumor formation usually have essential functions in 
maintaining homeostasis. They can be arranged in three major groups. The first group 
comprises genes that have the potential to initiate tumor progression by, for example, 
encoding proteins that stimulate cell growth, proliferation, migration and survival. Such 
genes are termed proto-oncogenes and frequently hyperactivated in tumor cells, thereby 
becoming oncogenes. In contrast, there are also genes that are usually affected by loss of 
function mutations, resulting in decreased activity, the so called tumor suppressor genes. 
Their gene products normally trigger cell cycle inhibition, cell adhesion, DNA repair and 
apoptosis and prevent cells from uncontrolled growth. The third group of genes that is often 
linked to malignancies is referred to as caretaker genes. They are involved in the 
identification and repair of DNA damage and the inactivation of mutagenic molecules before 
they can cause DNA damage to protect the integrity of the genome. Inactivation of these 
genes dramatically increases the chance for further mutations to occur and consequently the 
risk to develop cancer. 
The fundamental distinctive and complimentary capabilities, enabling tumor growth and 
metastasis, which are acquired during the multistep development of human tumors, are 
summarized in the hallmarks of cancer by Hanahan and Weinberg. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7: 
The hallmarks of cancer (Hanahan and Weinberg 2011). 
10 | P a g e  
 
Six core hallmarks have been already described in 2000 and are meanwhile well established. 
They comprise sustaining proliferative signaling, evading growth suppressors, resisting cell 
death, inducing angiogenesis and activating invasion and metastasis. Recently, the authors 
have revised their model and added four new hallmarks that are involved in the 
pathogenesis of some and perhaps all cancers. Two additional enabling characteristics are 
genome instability and tumor promoting inflammation. The other two capabilities, 
deregulating cellular energetics and avoiding immune destruction, are labeled as emerging 
hallmarks, because neither is generalized and fully validated yet. A schematic illustration is 
shown in Figure 7 and each of these ten hallmarks is briefly discussed below. 
The most fundamental trait of tumor cells involves their ability to sustain proliferative 
signaling. Normally, homeostasis of cell number is maintained by numerous control 
mechanisms that regulate cell growth and proliferation. In tumor cells, these control 
mechanisms are deregulated and chronic proliferation is allowed by, for example, somatic 
mutations that activate additional downstream pathways or disrupt negative feedback 
mechanisms that usually attenuate proliferative signaling. 
Additionally to the induction of positive-acting growth stimulating signals, tumor cells must 
also be able to evade growth suppressors. Due to loss of function mutations in tumor 
suppressor genes, cancer cells circumvent the powerful mechanisms that negatively regulate 
cell proliferation. One of these features comprises evasion of a mechanism termed contact 
inhibition, where normal cells stop to proliferate when cell-to-cell contacts are formed. 
Resisting cell death is another crucial feature that cancer cells have to acquire during their 
progression. Programmed cell death by apoptosis serves as a natural barrier to cancer 
development, triggered by physical stresses that cancer cells have to experience during their 
course of tumorigenesis or as a result of anti-tumor therapy. The apoptotic machinery is a 
complex mechanism composed of upstream regulator and downstream effector 
components. Somehow, cancer cells have become capable of disturbing this machinery, thus 
evading apoptosis. Additionally, the two other ways of cell death, autophagy and necrosis, 
have also tumor-promoting potential, by generating additional nutrients and recruiting 
inflammatory immune cells, respectively, which further release active regulatory factors 
triggering angiogenesis and tumor growth. 
Normally, most cell lineages in the body have a limited potential to divide. After a certain 
number of cell division cycles the cells enter senescence or crisis, followed by cell death. 
Occasionally, cells emerge from a population in crisis and become tumor cells, thereby 
enabling replicative immortality. An important role is played by telomerase, which prevents 
shortening of the telomeres and thus, senescence. 
Like all tissues, tumors require sustenance in form of nutrients and oxygen, as well as the 
ability to dispose of metabolic waste and carbon dioxide, which is normally provided by the 
vascular system.  
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The process of forming new blood vessels (vasculogenesis) and sprouting from existing ones 
(angiogenesis) usually occurs during embryonic development and in adult organisms during 
physiological processes like wound healing and the female reproduction cycle. In tumor cells, 
a so called angiogenic switch is permanently activated, allowing the tumor to sustain 
angiogenesis and thus assure its maintenance. 
The last of the six core hallmarks of cancer cells is their ability to activate invasion and 
metastasis, meaning that they have the potential to infiltrate surrounding tissues and 
further metastasize into other parts of the body and colonize there, using the blood or the 
lymphatic vessel system. For these processes, a regulatory program termed epithelia-
mesenchymal transition (EMT) plays an important role and is frequently hyperactivated in 
tumor cells. This program is reversed (MET) when the cells have reached their final location 
in other body parts and start to colonize there. The invasion/metastasis process is also 
accompanied by a switch from expression of E-cadherin, which is an antagonist of invasion 
and metastasis, to N-cadherin that is normally expressed in migrating neurons and 
mesenchymal cells during organogenesis.  
The acquisition of all these hallmarks largely depends on genome alterations. Thus, a general 
genomic instability and thus mutability is required to increase the mutation rate, providing 
the chance for tumorigenesis. Normally, genomic integrity is provided by the caretaker 
genes, which frequently get inactivated during the course of tumorigenesis through 
mutations or via epigenetic repression. 
The second enabling characteristic recently added to the core hallmarks is tumor-promoting 
inflammation. Some tumors are infiltrated by immune cells and mirror inflammatory 
conditions, which are designed to fight infections and heal wounds. During this inflammatory 
process, cells of the innate immune system release a variety of growth, survival and 
proangiogenic factors, thereby having widely appreciated tumor-promoting effects. 
Another additional hallmark, which seems to play a role in carcinogenesis and tumor 
progression, is deregulating cellular energetics. Not only deregulation of proliferation is 
required for cancer cells, which constantly grow and divide, they are also dependent on 
adjustments in energy metabolism in order to sustain their higher uptake rates of nutrients 
and energy. Tumor cells have acquired the capacity to reprogram the cellular metabolism, 
leading to a state termed aerobic glycolysis, in order to obtain the most effective support for 
continuous growth and proliferation. 
Evading immune destruction is a second, still unresolved issue in tumor formation. 
Normally, cells and tissues are constantly monitored by the immune system, especially T-and 
B-lymphocytes, macrophages and natural killer (NK) cells. This ever-alert immune 
surveillance is responsible for recognizing and eliminating the vast majority of developing 
cancer cells and tumors. According to this, tumors must have somehow managed to evade 
this immune destruction. 
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The ten hallmarks of cancer discussed above comprise the most important features 
characterizing cancer cells and discriminating them from normal tissues. Consequently, 
targeting these mechanisms is a very promising issue in anti-cancer therapy. 
 
1.2.2. Dysregulation of FGF signaling in tumorigenesis: 
FGF signaling mediates a powerful set of regulatory effects essential for a functional 
homeostasis via downstream signaling pathways, like promoting cell cycle progression, 
growth, migration, neoangiogenesis and inhibiting pathways of cell death. All components of 
the FGF-mediated signaling pathway sustain the potential of being strongly oncogenic. 
Therefore, dysregulation or loss of the regulation mechanisms, responsible for achieving 
intracellular balance, at any step can result in driving downstream components to promote 
cell growth beyond control. Consequently, FGF signaling is often associated with 
malignancies of epithelial as well as mesenchymal origin, contributing to most of the 
hallmarks of cancer. The underlying mechanisms causing alterations in FGFs and FGFRs 
driving FGF signaling are largely tumor-type specific and described below. 
 
Increased availability of ligands: 
Overexpression of FGFs might contribute to increased FGFR activation and unregulated 
signaling. FGF release from local reservoirs into the ECM deriving from overexpression by 
both, the tumor cells and/or the surrounding stroma cells, can lead to upregulation of FGF 
signaling. Consequently, FGFs act in an autocrine or paracrine manner, or both. The simplest 
way is that FGFs derive from the tumor cells themselves, but they can also be secreted by 
the stromal cells in response to a signal from the tumor and/or vice versa (Powers, McLeskey 
et al. 2000). Overexpression of secreted FGFs by the tumor itself, supporting autocrine 
signaling loops, is a common feature in many tumor types as shown in Table 2. The other 
possibility, that FGFs are secreted in response to the tumor from stromal cells has been 
reported with FGF5 in pancreatic cancer (Kornmann et al. 1997). 
Table 2: 
Fibroblast growth factors overexpressed in different tumor types, supporting autocrine signaling (Heinzle, 
Sutterluty et al. 2011). 
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Another alternative for and increased availability of FGF ligands may be due to the 
mobilization from their reservoirs in the ECM. In principal, there are two ways how FGFs can 
be released from the ECM. First, by the activity of FGF binding proteins that deliver the 
growth factors from their storage sites to their receptors and secondly, via enzymatic 
cleavage by heparanases or proteases, resulting in FGF release from the ECM (Powers, 
McLeskey et al. 2000). Both of them can potentially be deregulated and therefore disturb 
signaling homeostasis.  
Recently, a gene amplification leading to FGF19 overexpression has been identified in human 
hepatocellular carcinoma (Sawey et al. 2011), indicating that gene amplification is a further 
possibility for increased ligand levels. 
 
Activating mutations, amplifications and translocations of receptor genes: 
Somatic point mutations in FGF receptors that lead to increased FGF signaling have been 
found over the complete length of the gene, in the extracellular, the transmembrane, but 
most commonly in the kinase domain (Greenman et al. 2007). Depending on their location 
within the molecule, such mutations can alter ligand specificity, facilitate ligand binding and 
receptor dimerization or constitutively activate the receptor kinase domain (Haugsten et al. 
2010), all of them leading to enhanced FGF signaling. Mutated forms of FGF receptors have 
been identified in multiple types of cancer, such as those of the brain, head and neck, lung, 
breast, stomach, prostate, colon, uterus and bladder as well as in multiple myeloma 
(Haugsten, Wiedlocha et al. 2010). 
Overexpression of a gene can also be driven by aberrant transcriptional regulation caused by 
gene translocations, but more commonly, by gene amplification. Elevated levels of FGF 
receptors in comparison to normal tissue have been described in numerous human cancer 
types such as breast, head and neck, ovarian, bladder, stomach, prostate and brain cancer, 
sarcomas and multiple myeloma (Haugsten, Wiedlocha et al. 2010; Heinzle, Sutterluty et al. 
2011). In case of chromosomal rearrangements, the result is often a fusion protein, which is 
able to exhibit functional properties derived from each of the original proteins. These fusion 
proteins can act as potent oncogene, as for example in stem cell leukemia (Haugsten, 
Wiedlocha et al. 2010). 
 
Germline single nucleotide polymorphisms (SNPs) in FGFR genes: 
As mentioned before, a couple of germline single nucleotide polymorphisms (SNPs) in FGFRs 
that modulate receptor activity have been identified. Thus, these SNPs may also influence 
cancer risk, tumor aggressiveness and metastasizing ability (Haugsten, Wiedlocha et al. 
2010). The most prominent SNP is a glycine to arginine substitution in position 388 (G388R) 
of the transmembrane region of FGFR4.  
14 | P a g e  
The FGFR4Arg variant has been shown to be more stable than the FGFR4
migration, it leads to a more aggressive tumor behavior 
effect has been reported for breast, prostate, colon and lung cancer and may also be related 
to therapy resistance (Heinzle, Sutterluty et al. 201
and their relation to cancer is shown in table 3 
 
Table 3: 
Genetic alterations in FGF receptors related to cancer (modified from 
 
 
Alterations of FGFR splicing –
Switching between alternatively spliced isoforms of FGF receptors can also lead to 
imbalanced FGFR signaling and thus promote tumo
receptor variants. 
Alternative splicing also determines the ligand binding specificity, more precisely splicing of 
the IgIII domain, creating the IIIb and IIIc isoforms of FGFR1
expressed in epithelial cells, whereas the IIIc receptor variant is 
of the mesenchyme. In contrast, the ligands for the IIIb isoforms are usually expressed by 
mesenchymal cells and vice versa, creating a paracrine FGF
Consequently, altered FGFR isoform expression broadens the rang
stimulate tumor cells and may result in autocrine stimulation 
 
Gly
(Bange, Prechtl et al. 2002)
1). A summary of FGF receptor alteration 
(Turner and Grose 2010). 
Turner and Grose 2010)
 isoform switch: 
r growth by creating more oncogenic 
-3. Normally, the IIIb isoform is 
predominantly
-mediated tissue crosstalk. 
e of FGFs that can 
(Haugsten, Wiedlocha et al. 
 and, inducing cell 
. This 
. 
 found in cells 
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2010; Heinzle, Sutterluty et al. 2011). This isoform switch, which can also be part of a general 
epithelial-mesenchymal transition (EMT) may play a role in tumor metastases and is related 
to increased invasiveness in bladder and prostate cancer (Chaffer et al. 2006). 
 
Impaired termination of FGF signaling: 
Impaired downregulation of FGFR activity can also affect signal duration. Normally, negative 
feedback loops or activated MAPK phosphatases, as well as Sprouty or Sef proteins strictly 
regulate signal attenuation. Termination of FGFR signaling is mediated through 
dephosphorylation or phosphorylation events, or endocytosis and degradation of the 
receptors in lysosomes (Haugsten, Wiedlocha et al. 2010). Accordingly, expression of 
Sprouty and Sef proteins is frequently downregulated in different tumor types and this may 
also contribute to malignancy and tumor progression. Decreased levels of Sprouty proteins 
are reported in non-small cell lung cancer (NSCLC), breast and prostate cancer, 
hepatocellular carcinoma and lymphoma (Heinzle, Sutterluty et al. 2011) and Sef was 
observed to be downregulated in cancers of breast, prostate, ovaries and thyroid (Zisman-
Rozen et al. 2007). 
 
Neoangiogenesis: 
In addition to autocrine effects, FGFs produced by tumor cells may also exert paracrine 
effects on surrounding cells, such as vascular endothelial cells. In the context that FGF signals 
stimulate endothelial cell proliferation and activate proteins that are essential for 
angiogenesis, FGFs are released from cells that decay in the necrotic center of large tumors. 
Those then function as an angiogenic switch to drive neovascularization (Mignatti and Rifkin 
1991; Compagni et al. 2000). Consequently, FGF signaling also functions as an essential 
mechanism for a tumor to assure its own nutrient supply as well as connection to the 
vascular system, which further gives rise to the opportunity to metastasize. This process has 
been reported for example in melanoma (Ria et al. 2010). 
 
1.2.3. FGF signaling and tumor suppression: 
Many studies have linked fibroblast growth factors to malignant progression, especially 
when FGF signaling is hyperactivated and/or deregulated. However, FGFRs have also been 
suggested to have tumor suppressive activities. In several human cancer types, such as 
bladder, liver, salivary gland and prostate cancer, FGF receptors, primarily FGFR2 have been 
reported to be downregulated. Additionally, several loss-of-function mutations of FGFR2 
have been found in melanoma. These data indicate a possible tumor-suppressive role of 
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FGFR2 in carcinogenesis, though, in other cancer types, activating mutations and 
overexpression of FGFR2 have been observed. 
1.2.4. Targeting FGF signaling for therapy: 
Since the FGF/FGFR axis has been identified as one of the major drivers of malignant growth 
and metastasis, much research is focused on targeting FGF signaling for cancer therapy. In 
vitro experiments already showed that inhibition of FGF-mediated signals lead to reduced 
cell growth and migration in multiple myeloma, glioblastoma, bladder, lung and colon cancer 
(Heinzle, Sutterluty et al. 2011).  
The most common strategy for clinical applications is intervention at the protein level. 
Pharmaceutical companies have developed several small molecule tyrosine kinase inhibitors 
targeting the FGF receptors that are currently in the early phases of clinical trials. Due to the 
high homology of the kinase domains, it is very difficult for these inhibitors to obtain FGFR 
subtype specificity. Furthermore, related growth factor receptors such as VEGFR, EGFR and 
PDGFR are also affected. Targeting multiple kinases may have some advantages by 
additional and synergistic effects but also increases the risk of systemic side effects.  
A more specific inhibition of FGF signaling with fewer side effects may be provided by the 
development of blocking antibodies targeting specific FGFR subtypes and FGF ligand traps. 
Ligand traps are soluble fusion proteins containing the extracellular FGFR domain that are 
able to bind FGFs but, due to their lack of an intracellular domain, transmit no further 
signals. Optimally, these approaches can be titrated to reduce the hyperactivated signals to 
physiological levels instead of completely erasing them (Turner and Grose 2010; Heinzle, 
Sutterluty et al. 2011). 
 
1.3. Malignant Pleural Mesothelioma: 
 
1.3.1. Epidemiology, general characterization and histological subtypes: 
Human malignant pleural mesothelioma (MPM) is the most common type of mesothelioma 
(70%) - one of the most aggressive human tumors that arises from mesothelial-lined surfaces 
or sub-mesothelial cells - that affects the pleura (Nguyen 2000). The malignancy is 
characterized by frequent resistance to chemo- and radiotherapy, poor outcome and limited 
therapeutic options. The median survival from diagnosis is 9-12 months (Robinson et al. 
2005). At least 80% of mesothelioma cases stand in a direct causal relation with asbestos 
exposure (Powers and Carbone 2002), but Simian Virus 40 (SV40), radiation and genetic 
predisposition have also been associated with mesothelioma development. Until the second 
half of the 20th century MPM was almost unknown, but during the last decades, the 
incidence increased significantly to about 10000 cases worldwide per year (Bianchi and 
Bianchi 2007) and is expected to double within the next 20 years.  
  
Two thirds of the patients with a mesothelioma diagnosis are between 50 and 70 years old 
and the incidence is higher in men t
better long-term survival than men 
remarkably varies from one county to another, the highest incidence rates are observed in 
Australia, Great Britain, Belgium and the Netherlands. 
These hot-spot areas for mesothelioma correspond wi
asbestos use during the 1970s, such as shipbuilding and asbestos
situation also stands in context with the high mean latency period between first exposure to 
asbestos and dying from mesothelioma, w
fact that 80% of the patients suffering from mesothelioma are male 
2005). So, the curve of increasing mesothelioma incidence mirrors the curve of the 
widespread global increase in asbestos use that has occurred some decades previously.
Anatomically, malignant mesothelioma is situated within the
membrane that encloses several organs and body cavities. 
In early stages of the disease, the tumor 
appears as multiple nodules on the 
surface of both, the visceral pleura, which 
covers the lung, and the parietal pleura, 
which is attached to the chest wall. 
During further progression, these nodules 
coalesce, forming a sheet of tumor that 
surrounds the lung and commonly 
invades the pericardium, the diaphragm 
and the underlying parenchyma 
2010) as shown in Figure 8. Usually, the 
right pleura is more commonly affected 
due to its larger surface area. 
Other sites where mesothelioma occurs are the peritoneum and rarely the pericardium and 
the tunica vaginalis testis.  
Based on the constitution of the tissue, MPM can be classified into three main histological 
subtypes. The most common one is the epitheloid subtype, with an incidence of 50
followed by mixed or biphasic with 20
2010). Specific histotypes have been referred to different survival rates, indicating a better 
prognosis for patients suffering from mesothelioma of the epitheloid subtype 
Libutti et al. 2003; Chirieac and Corson 2009)
 
han in women. Generally, women also appear to have a 
(Wolf et al. 2010).  Mesothelioma incidence also 
 
th the sites of industries with high 
-cement industry. This 
hich is about 40 years (Yates et al. 1997)
(Robinson and Lake 
 tunica serosa, a smooth 
 
(Rudd 
-40% and sarcomatoid with approximately 1
.  
Figure 8: 
Anatomical sites of malignant pleural mesotheli
(www.mesotheliomacenter.org)
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The epitheloid histotype is characterized by papillary structure with generally well-defined 
and uniform-shaped cells but also displays several patterns including tubulopapillary, 
microcystic and glandular. Due to the structural similarity to adenocarcinoma, the 
histological diagnosis can be difficult.  
In contrast, the sarcomatoid subtype consists of elongated spindle cells, which are irregularly 
arranged and not uniform in shape. The biphasic subtype shows a mixture of both, 
epitheloid and sarcomatoid elements (Rudd 2010). Figure 9 shows histological pictures of 
the three mesothelioma subtypes. 
 
 
 
1.3.2. Asbestos, Simian Virus 40 and other risk factors: 
Asbestos: 
As many as 80% of mesothelioma patients have been exposed to asbestos (Powers and 
Carbone 2002). This epidemiological observation indicates a strong relationship between 
asbestos and mesothelioma development, which is further supported by numerous animal 
studies. Until the second half of the 20th century, asbestos was widely used in construction 
and shipbuilding industry, due to its excellent properties like tensile strength, flexibility and 
resistance to heat, seawater, chemical and electrical damage. But since concerns about the 
hazardous effects on health came up, the use of asbestos becomes forbidden in more and 
more countries, since 2005 in the whole European Union.  Today, asbestos has been 
replaced by safer materials, but is still frequently used in many parts of the world. 
Asbestos consists of small mineral fibers, which are inhaled into the lung causing irritation of 
the pleura. Thereby the shape and length-to-width ratio of the fibers play an important role 
and determine how deeply they are inhaled and if they are capable of penetrating the lung 
and entering the pleural space (Robinson, Musk et al. 2005).  
Figure 9: 
The three histological subtypes of human malignant mesothelioma: epitheloid (A), sarcomatoid (B) and biphasic (C) 
(Feldman et al. 2003). 
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Smaller fibers are phagocytozed and successfully removed from the lung, but in contrast, 
long and thin fibers can penetrate the lung and irritate the pleura by repeatedly scratching 
the mesothelial surface, causing prolonged cycles of damage, repair and local inflammation.  
This process of continuous irritation may lead to pleural plaques, fibrosis and mesothelioma. 
Additionally, asbestos fibers have the potential to interfere with the mitotic segregation, 
resulting in chromosome alterations such as aneuploidy and double strand breaks 
(Hesterberg and Barrett 1985). Generation of hydroxy radicals and superoxide anions during 
phagocytosis also induces DNA damage and strand breaks. Another feature facilitating 
mesothelioma development caused by asbestos is stimulation of macrophages to produce 
lymphokines and oxyradicals that depress immune function and kinase-mediated signaling.  
Furthermore, asbestos was found to induce autophosphorylation of the EGF receptor, 
thereby persistent activating the MAPK pathway and triggering cell proliferation and growth 
(Powers and Carbone 2002; Robinson, Musk et al. 2005). 
 
Simian Virus 40: 
Simian Virus 40 (SV40) is an oncogenic virus that can transform human cells and induce 
tumors. Since up to 60% of human mesotheliomas were reported to contain SV40 DNA, the 
small, double-stranded polyomavirus has been implicated as a cofactor in the causation of 
human malignant mesothelioma (Robinson, Musk et al. 2005). In contrast to asbestos, 
however, the contribution of SV40 to mesothelioma development is controversial. Although 
this virus is endogenous in rhesus monkeys, it is now widespread among the human 
population too. How exactly the virus has been transferred from the monkeys to humans 
remains unclear but the vast bulk of transfer may have occurred during the 1950s and early 
1960, when SV40-contaminated poliovaccine was administered worldwide. Furthermore, the 
virus is thought to be contagiously transmitted horizontally in human beings (Zanella et al. 
1996). 
The detailed mechanisms of SV40 tumorigenesis are only partly understood yet. Inside of its 
host, the virus produces two oncogenic proteins, the large and the small t-antigen, Tag and 
tag, with molecular weights of 90 kDa and 17 kDa, respectively. The large T-antigen is usually 
found in the nucleus of infected cells, inducing numerical and structural chromosome 
aberrations and insulin-like growth factor (IGF) expression to stimulate cell proliferation. In 
contrast, the small t-antigen is found in the cytoplasm, stimulating MAPK and other 
proliferation-related signaling pathways. Both antigens are involved in the inhibition of 
tumor-suppressor genes such as p53 and pRb. Furthermore, SV40 has been shown to induce 
telomerase activity, which may also play a role in cancer development (Foddis et al. 2002). 
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Radiation: 
There are also a few studies referring radiation to mesothelioma development.  In a few 
cases, relatively young patients who had received radiotherapy because of other tumors 
developed mesothelioma (Cavazza et al. 1996).  
 
Genetic factors:  
Endemic mesothelioma occurs in three Turkish villages, Karain and Tuzkoy and Sarihidir, 
which are located in Cappadocia, where every second adult dies of pleural mesothelioma. 
This high incidence is due to the permanent exposure to erionite, one of the six asbestos 
types, which is present in rocks, the inhabitants used to build their houses with (Carbone et 
al. 2007). Recently, it was observed that the disease occurs only in certain families, whereas 
mesotheliomas do not develop in others, regardless of the environmental exposure. Within 
these affected families, studies have shown that mesothelioma is inherited in an autosomal 
dominant pattern. This evidence suggests that genetics may also play a key role in 
determining susceptibility to the carcinogenic effects of asbestos  (Roushdy-Hammady et al. 
2001). 
 
1.3.3. Diagnosis, staging and prognosis: 
Typically, mesothelioma presents with breathlessness and chest wall pain due to the 
development of a pleural effusion. Constitutional symptoms such as anorexia, weight loss, 
fatigue, general malaise and profuse sweats at night can occur, but generally appear at later 
stages of the disease and are associated with a poor prognosis (Robinson, Musk et al. 2005). 
Occasionally, patients show no symptoms and the disease is found on a routine examination. 
When mesothelioma is suspected, accurate and rapid diagnosis is very important for further 
clinical management of the patient. In addition to clinical examinations, a careful 
occupational history with respect to asbestos exposure should be taken. 
Pleural effusion and thickening, diffuse lobular masses and plaques can be visualized by 
chest X-ray, which is further supported by modern imaging techniques such as computed 
tomography (CT), magnetic resonance tomography (MRT) and positron emission 
tomography (PET) scans (Kim et al. 2001). Although imaging can indicate the presence of 
mesothelioma, it cannot provide a definitive diagnosis. So, cytological analysis of the pleura 
fluid is performed, but most important is the endoscopic examination of the thorax 
(thoracoscopy) with an attendant biopsy. A common problem in diagnosis is distinguishing 
mesothelioma from adenocarcinoma, especially when the tumor has invaded the pleura 
(Robinson, Musk et al. 2005).  
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Pathological diagnosis is essential if any specific therapy is to be considered and histological 
classification also gives useful prognostic information, indicating a worse prognosis for the 
sarcomatoid and biphasic histotypes. Other factors predicting poor prognosis are poor 
performance status, low hemoglobin, elevated white-cell and platelet counts, increased 
vascularity and evidence of SV40 DNA in the tumor (Wang et al. 2004; Robinson, Musk et al. 
2005).  
Furthermore, there is increasing interest for blood-based markers for mesothelioma. One 
example is the serum mesothelin-related protein (SRMP), a soluble form of mesothelin, a 
surface protein thought to be important in mesothelial cell adhesion. SRMP has been shown 
to be elevated in more than 60% of patients with malignant mesothelioma at the time of 
diagnosis. Since SRMP levels increase with tumor progression and decrease with its 
regression or resection, they may be useful in monitoring therapy (Robinson, Musk et al. 
2005). The same has also been shown for soluble mesothelin (SM) and megacaryocyte 
potentiating factor (MPF). Low baseline osteopontin levels have been associated with better 
overall survival (Hollevoet et al. 2011). Recently, C-reactive protein (CRP) has been 
recognized as a predictive marker. High serum levels have been associated with poor 
outcome of patients receiving multimodality therapy (Ghanim 2012). 
The mode of subsequent therapy is based on specific parameters given by examination and 
the level of progression of the disease, which is staged referring to the widely used staging 
system devised by the International Mesothelioma Interest Group (IMIG). The classification 
is based on a TNM (tumor-node-metastasis) system for malignant tumors, as shown in Table 
4 (Rusch 1996). This system describes and summarizes the size and distribution of the tumor 
itself, the involvement of lymph nodes and the appearance of distant metastases, leading to 
an arrangement in four different tumor stages. 
An alternative classification system has already been proposed in 1976 and is referred to as 
the Butchart Staging System (Butchart et al. 1976). In contrast to the TNM system devised by 
the IMIG, which is based on the staging system of lung cancer, the Butchart system is 
especially designed for mesothelioma. Thus, there are several differences  between the two 
systems (Butchart 1999). Currently the International Association for the Study of Lung 
Cancer (IASLC) and IMIG are working on a new staging and disease classification. 
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Table 4: 
The international TNM tumor staging system (Rusch 1996). 
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Table 5: 
The Butchart tumor staging system (Butchart 1999). 
 
 
 
 
 
 
 
 
 
 
Due to the very unspecific and late-apparent symptoms, the majority of MPM cases is 
diagnosed in an already progressed state, at least at Stage II of the TNM system. Thus, in 
most cases, only palliative therapy can be offered, with the aim of improving the quality of 
life and prolonging the patient’s lifetime. The median survival time of these patients lies 
between 5 and 8 months, those with favorable prognostic parameters survive between 10 
and 18 months (Steele 2002). The actual causes of death are normally respiratory 
insufficiency and secondary pneumonia. However, a small minority of patients is considered 
for surgical resection, chemo- and radiotherapy with a potentially curative intention. 
Although this group has a better prognosis, the 5-year survival lies below 15% (van Ruth et 
al. 2003).  
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1.3.4. Therapeutic approaches: 
Until fairly recently, MPM was considered as an untreatable and incurable disease, that only 
allows palliative arrangements. Although during extensive research in the last decades, 
several possible therapeutic approaches have been established, the poor prospects 
displayed above clearly show the urgent need for the development of new and more 
effective therapies for mesothelioma. 
 
Chemotherapy: 
To date, no chemotherapy regimen for mesothelioma has proven curative, but several are 
valuable for palliative treatment. Most commonly used is a combination of pemetrexed and 
cisplatin, both inhibiting DNA synthesis, which has been shown to decrease tumor burden as 
well as improve survival, lung function and symptoms such as pain and breathlessness. 
Gemcitabine combined with cisplatin has also been observed to offer similar palliative 
effects (Robinson, Musk et al. 2005). 
 
Radiotherapy: 
Generally, the results of attempting radiotherapy to treat mesothelioma also have been 
largely disappointing. Because of the widespread diffuse nature of the tumor, covering most 
of the pleural surface as well as the interlobular fissures, it is nearly impossible to undertake 
radical radiotherapy with curative intention without affecting and damaging lung, heart, the 
spinal cord and other organs. But radiotherapy can be delivered for pain control or symptom 
prevention in a palliative setting (Robinson, Musk et al. 2005; Stahel et al. 2010). 
An exception is the use of local postsurgical radiotherapy as a part of multimodality therapy 
discussed below, which has been shown to be effective in the prevention of tumor cell 
seeding within the postoperative site. Another application of radiotherapy in MPM is 
prophylactic VATS (video-assisted thoracoscopic surgery) -port irradiation to prevent tumor 
cell spilling and procedure tract metastasis after surgical intervention (Froment et al. 2011).   
 
Surgery: 
Palliative surgery has the main goal to obtain effective pleurodesis to improve the patient’s 
life quality. Pleurodesis is a procedure that causes the pleura to stick together, preventing 
the accumulation of fluid in the space between the membranes and thus breathing 
difficulties and pain. It is achieved by placing an irritant, most commonly talc powder or 
tetracycline, in the space between the pleura, leading to inflammation followed by pleura 
conglutination.  
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In case of a potentially curative therapy, there are two surgical approaches in order to 
remove the entire tumor mass. Extrapleural pneumonectomy (EPP) is the more radical 
variant, which involves removal of the whole lung, both layers of the pleura, parts of the 
diaphragm and, if affected, the pericardium. Due to its radical nature, only few patients are 
suitable for  EPP, the operative mortality is now around 6% in experienced centers 
(Robinson, Musk et al. 2005). In the other technique, pleurectomy/decortication (P/D), the 
lung is left in place and only the two layers of the pleura are resected. In both cases, the 
resected linings are reconstituted with synthetic materials, usually Gore-TexTM and Vicryl 
mesh (Sugarbaker and Wolf 2010).  
 
Multimodality therapy: 
Today, the most promising therapeutic approach for patients with good prognosis and 
overall condition is the multi- or trimodality therapy. This approach includes induction 
chemotherapy, followed by EPP and radical postsurgical radiotherapy.  This combined 
procedure has been shown to be much more effective than single treatment with surgery, 
chemo- or radiotherapy. 
 
Gene therapy, immunotherapy and other approaches: 
MPM has been the target of two gene therapy approaches. The first is known as suicide 
gene therapy and involves the viral transfer of a DNA molecule encoding the herpes simplex 
virus thymindine kinase. The enzyme by itself has no effect but, after the administration of 
ganciclovir, becomes capable of converting the drug into a toxic metabolite that destroys the 
tumor cells (Sterman et al. 1998). The second type of approach involves immune-modulatory 
gene therapy, where inflammation processes are mimicked by the local delivery of a vector 
producing cytokines within the tumor to trigger autoimmune destruction. Both approaches 
are still in early stages of development and though gene therapies seem to be promising, 
they have no established place in standard mesothelioma therapy (Robinson, Musk et al. 
2005). 
Alternatively, immunotherapy has also been considered for mesothelioma treatment, 
mostly in combination with other therapeutic modalities. The intention of this approach is to 
boost the patient’s weak immune system and anti-tumor response to induce tumor 
regressions. Immunotherapy may also be promising, but is still in the beginning of 
development (Robinson, Musk et al. 2005). 
Another local therapy approach is a hyperthermic intraoperative intracavitary cisplatin 
perfusion after an extrapleural pneumonectomy (EPP). This therapy consists of a 42°C warm, 
high dosed cisplatin lavage of the chest cavity directly after resection of the lung during the 
EPP.  
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Though this procedure may enhance the local control in the chest, it could not effectively 
improve patient survival. Thus, the overall outcome was disappointing (Tilleman et al. 2009). 
A relatively new approach is the photodynamic therapy. Therefore, a sensitizing drug is 
administered, followed by intrapleural illumination of the tumor by lasers. When the light 
meets the drug in the presence of oxygen, toxic oxygen radicals are generated that damage 
the cells and induce necrosis. The problem of uneven distribution of the tumor, which also 
covers the lung fissures, is solved by usage of light-scattering media. Photodynamic therapy 
is an effective method for cytoreduction, but long term responses have not been noted 
(Robinson, Musk et al. 2005). 
 
Targeted Therapy: 
In the past decade, targeted therapy, a novel mechanism of cancer treatment that differs 
from traditional cytotoxic chemotherapy or radiotherapy, has become more and more 
prominent. This strategy is based on interfering with key alterations in molecular pathways 
that are unique for cancer cells, contributing to their malignant pheonotype. Research 
activity has shown that most tumors are characterized by cancer-type specific alterations 
and now the focus lies on finding compounds that directly target these molecules (Gerber 
2008). 
For instance, tyrosine kinases are frequently altered in cancers and inhibition of their activity 
can lead to disruption of survival pathways in tumor cells. Targeting angiogenesis, which is 
essential for survival of solid tumors, has also been validated for anti-cancer therapy. Various 
angiogenesis, cell cycle pathway and EGFR inhibitors such as vatalanib, sunitinib, gefitinib 
and erlotinib have been proved useful in different cancer types like renal cell carcinoma and 
lung cancer. Disappointingly they have been observed to be ineffective in MPM. However, 
many studies and clinical trials of new small-molecule inhibitors and specific antibodies are 
currently in progress (Fennell et al. 2008).  
A second approach is targeting epigenetic mechanisms. Tumor suppressor genes, for 
instance, are frequently methylated and thus inactivated in tumors. Consequently, histone 
deacetylase (HDAC) inhibitors such a PXD101 are associated with apoptosis and 
antiproliferative activity and currently evaluated in mesothelioma (Fennell, Gaudino et al. 
2008). Recently, a study reported that inhibition of the polycomb repressor complex 2 
(PRC2), which is also involved in heterochromatin formation and repression of gene 
expression, led to re-expression of tumorsuppressor genes and thus reduced proliferation 
and migration in MPM cells in vitro and in vivo (Kemp et al. 2011). 
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1.4. Aims of study: 
 
Malignant pleural mesothelioma (MPM) is a highly aggressive tumor showing a generally 
poor prognosis with a median survival of 9 to 12 months. It is strongly related to past 
asbestos exposure and affects mesothelial surfaces such as the pleura. The disease is 
characterized by frequent resistance to chemo- and radiotherapy, poor outcome and limited 
therapeutic options. For this reason the development of new therapeutic approaches such 
as targeted therapy is urgently needed. 
Fibroblast growth factors (FGF) and their high affinity receptors (FGFR) comprise a signaling 
system that is involved in physiological processes such as embryonic development and 
wound healing as well as in regulatory effects essential for a functional homeostasis, like 
promoting cell cycle progression, growth, migration, neoangiogenesis and inhibiting 
pathways of cell death. Consequently, all components of the FGF-mediated signaling 
pathway sustain the potential of being strongly oncogenic and driving tumor progression. 
The FGF receptor axis has been identified as potential tumor target in several tumor types 
such as multiple myeloma, glioblastoma, bladder, lung and colon cancer. Thus, it may also be 
a potential candidate target for mesothelioma treatment but has not been systematically 
investigated in MPM so far. 
 
The aims of the here presented study were 
1) to provide a systematic analysis of the expression of all four FGFRs including 
different isoforms and the 22 FGFs in a panel of mesothelioma cell lines 
compared to the non-malignant SV40 Tag-transformed mesothelial cell line 
Met5a as well as in patient-derived paraffin embedded tissue samples.  
 
2) to examine the impact of FGFR-mediated signaling on cell proliferation, 
migration, invasion and three-dimensional spheroid growth after stimulation of 
mesothelioma cell lines with FGF2 or FGFR inhibition via a genetic construct and 
specific small molecule inhibitors, as well as analyzing the underlying changes in 
the downstream signaling pathways. 
 
3) to evaluate the FGFR axis as potential therapy target by investigating the 
sensitivity of mesothelioma cells to currently used chemotherapeutics and 
irradiation in combination with inhibition of the FGFR pathway.  
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2. MATERIALS AND METHODS: 
 
2.1. Cell culture: 
 
All cell lines were maintained in MEME or RPMI-1640 medium containing 10% FCS in a 
humidified atmosphere of 5% CO2 at 37°C. Cells were cultured in T25 tissue culture flasks 
and passaged twice a week at a ratio of about 1:20. For that purpose, cells were washed 
once with Dulbecco’s PBS +/+ (PAA) and then detached by addition of trypsin/EDTA (Sigma). 
Three-dimensional cultures were grown in ultra low attachment 24-well plates (Costar) in 
serum-free DMEM containing 20 ng/ml FGF2, 20 ng/ml EGF, 0.5 x B27 and 1% P/S (stem cell 
medium, SCM). 
All used cell lines, their histological subtypes, standard growth media and source are listed in 
Table 6. 
Table 6:  
List of cell lines used for in vitro experiments. 
 
Cell line 
Histological 
Subtype 
Standard Growth 
Medium 
Source 
Met5a 
SV40 Tag - immortalized 
mesothelial cell line 
RPMI+10% FCS ATCC 
SPC111 Biphasic MPM RPMI+10% FCS 
R. Stahel 
University of Zurich 
SPC212 Biphasic MPM RPMI+10% FCS 
R. Stahel 
University of Zurich 
CRL5820/NCI-H28 Epitheloid MPM RPMI+10% FCS ATCC 
P31 Epitheloid MPM MEME+10% FCS 
K. Grankvist 
Umea University 
P31 res1.2 Epitheloid MPM MEME+10% FCS 
K. Grankvist 
Umea University 
I2 Epitheloid MPM RPMI+10% FCS 
A. Catania 
Milano 
M38K Biphasic MPM RPMI+10% FCS 
V. L. Kinnula 
University of Helsinki 
VMC6 Epitheloid MPM RPMI+10% FCS 
W. Klepetko 
Medical University Vienna 
VMC11 Epitheloid MPM RPMI+10% FCS 
W. Klepetko 
Medical University Vienna 
VMC12 Epitheloid MPM RPMI+10% FCS 
W. Klepetko 
Medical University Vienna 
VMC14 Epitheloid MPM RPMI+10% FCS 
W. Klepetko 
Medical University Vienna 
VMC20 Epitheloid MPM RPMI+10% FCS 
W. Klepetko 
Medical University Vienna 
VMC23 Biphasic MPM RPMI+10% FCS 
W. Klepetko 
Medical University Vienna 
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VMC28 Epitheloid MPM RPMI+10% FCS 
W. Klepetko 
Medical University Vienna 
VMC31 Epitheloid MPM RPMI+10% FCS 
W. Klepetko 
Medical University Vienna 
 
2.2. MPM tissue samples: 
 
Tumor tissue samples (n=60) derived from patients suffering from Malignant Pleural 
Mesothelioma after surgical intervention at the Division of Thoracic Surgery, Department of 
Surgery, at the Medical University of Vienna between 1993 and 2011. All samples are 
histologically proven as mesothelioma, fixed in formalin and embedded in paraffin. For 
immunohistochemical staining, samples were cut in sections of 4 µm. 
 
2.3. Cell treatment & drugs: 
 
2.3.1. Recombinant Growth Factors: 
Cells were treated with recombinant human fibroblast growth factor 2 (rhFGF2) (Sigma) and 
recombinant human epidermal growth factor (rhEGF) (Sigma), diluted in PBS. The usual 
standard treatment concentration was 10 ng/ml. 
 
2.3.2. Small molecule inhibitors: 
PD166866 was generously supplied by Pfizer Global Research and 
Development. The substance is an ATP competitive tyrosine kinase 
inhibitor that specifically inhibits FGFR1 and was also shown to 
inhibit FGF2-mediated receptor autophosphorylation (Panek, Lu et 
al. 1998). 
SU5402 is a small molecule tyrosine kinase inhibitor that blocks the 
FGF-Receptors, especially FGFR1, but also VEGFR (Mohammadi et 
al. 1997). Additionally, at high concentrations, SU5402 has an 
effect on PDGFR. The substance was obtained from Calbiochem.  
Both agents were tested in a concentration range from 1 to 25 µM. 
Concentrations used for combination assays are listed in Table 7 
below. The molecular structures of PD166866 and SU5402 are 
shown in Figure 10.  
Figure 10: 
Molecular structures of SU5402 and 
PD166866. Figures adapted from 
Calbiochem Datasheet and Panek et 
al. 1998. 
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2.3.3. Genetic constructs:
Dominant-negative FGFR1 adenovirus:
As an alternative approach to inhibit FGFR mediated signals, cells were transduced with 
adenoviruses expressing a GFP
established in the Institute of Cancer Research in Vienna. 
As control, a virus containing only GFP was used. Cells were transduced at different MOIs 
(multiplicity of Infection, virus particles per cell). The appropriate dilution was calculated 
according to the ifu/µl (infectious units per µl) of the viral stocks, stored at 
For adenoviral transduction, depending on the experimental setting and the reaction 
volume, appropriate numbers of cells were seeded in 6
the viral suspension was added drop
experiments were performed in a biosafety level 2 lab. The day after transduction, medium 
was changed or, for further processing outside the biosafety lab
washed at least 3 times with PBS. Efficiency of transduction was checked by fluorescence 
microscopy. Representative pictures are shown in Figure 11.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FGFR2 IIIb/IIIc splicing reporter construct:
 
To visualize splicing events generating the IIIb and IIIc variants of FGFR2, cells
transfected with a reporter construct (pRGIIIc), which was kindly provided by Mariano 
Garcia-Blanco from the Duke University Medical Center (Durham, N.C., USA). 
This minigene construct expresses different fluorescent proteins, depending on the use o
different splice sites taken from the FGFR2 IIIb/IIIc variants 
of exon IIIc results in a fusion protein in frame, containing EGFP (green) and ending at a stop 
codon (stop2).  
Figure 11: 
P31 cells 24 hours after adenoviral transduction. The dominant
(MOI: 10) is located at the plasma membrane, whereas the GFP control (MOI: 3) 
is expressed all over the cytoplasm.
 
 
 
 
-tagged dominant-negative FGFR1 construct (Ad
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(Oltean et al. 2008)
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 When the IIIc exon is skipped (which is the case when the IIIb variant of FGFR2 is expressed), 
a frameshift occurs and a DsRED (red) protein ending at a frameshift
formed stop codon (stop 1) is generated. A schematic illustration is shown in Fig
(Holzmann 2012). Summarized, cells expressing the FGFR2 IIIb variant will show a red 
fluorescence, whereas cells that express the IIIc splice 
at appropriate wavelengths. 
 
 
 
 
For transfection, 2 x 105 cells were seeded in a 6
medium. The following day, cells were transfected with the pRGIIIc plasmid using TurboFect 
in vitro Transfection Reagent (Fermentas). Medium was removed and the volume of fresh 
medium was increased to 4 ml per 6
plasmid DNA were mixed with 400 µl serum
and incubated 20 minutes at room temperature. Then, the TurboFect/DNA mixture was 
added drop-wise to the medium and the plates rocked gently. After 24 hours, medium was 
changed and, where indicated, drug treatment was started. Transfection efficiency and 
possible effects of treatment were checked under the fluorescence microscope (
Nikon). 
 
2.3.4. Chemotherapeutics:
Cisplatin is a platinum-containing, antineoplastic and alkylating agent with broad activity, 
which is commonly used in chemotherapy and effec
esophagus, bladder, ovary cancer and mesothelioma. The substance was obtained from 
Sigma. After diffusion into the cell, the chloride is replaced by water, resulting in the 
positively charged, active form. Cisplatin
forming intra- and intermolecular crosslinks and thereby inhibiting DNA replication
2011).  
Figure 12: 
Schematic illustration of the FGFR2 IIIb/IIIc spice variant reporter construct 
successfully transfected SPC111 cells 3 days after transfection expressing either FGFR2 IIIb (DsRED
(EGFP). 
 
variant appear in green when excited 
-well plate in a total volume of 2 ml growth 
-well, as requested in the protocol. Meanwhile, 4 µg 
-free medium and 8 µl of the TurboFect reagent 
 
tive in for example lung, head and neck, 
 reacts with the N7 atoms of adenine and guanine 
(Holzmann 2012)
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Pemetrexed (Alimta) was supplied by Eli Lilly and Company and is a chemotherapy drug that 
is used for treatment of breast, colon and pancreatic and non-small cell lung cancer. 
Currently, pemetrexed in combination with cisplatin, is the method of choice for 
mesothelioma chemotherapy treatment. The substance prevents the synthesis of new DNA 
and RNA by inhibiting three enzymes, which are essential for purine and pyrimidine 
nucleotide synthesis (Hazarika et al. 2005). 
Trabectedin (Yondelis) was obtained from PharmaMar. Originally derived from a marine 
organism the substance is used for treatment of soft tissue sarcomas and is undergoing 
clinical trials for other cancer types. Trabectedin leads to DNA backbone cleavage and 
therefore to cell apoptosis by producing superoxide near the DNA strand, but the actual 
biological mechanism of action is not yet known exactly (D'Incalci and Galmarini 2010). 
Gemcitabine (Gemzar) is an anti tumor agent that is used for lung, breast, pancreatic and 
bladder cancer treatment. The nucleoside analog was obtained from Eli Lilly and Company 
and causes cell apoptosis by replacing the cytidine during DNA replication, leading to 
abortion of synthesis (Rudin et al. 2011). 
Vinblastine binds tubulin, thereby inhibiting the formation of microtubules. Thus, the 
mitotic spindle, which is required for cell division, cannot assemble and cell proliferation is 
prevented (Jordan and Wilson 2004). Vinblastine is used to treat different kinds of cancer, 
including Hodgin’s lymphoma, lung, breast, head and neck and testicular cancer. The 
substance was obtained from Sigma. 
 
All drugs were used for proliferation assays in combination with the specific FGFR tyrosine 
kinase inhibitors SU5402 and PD166866. A list of the applied concentrations is provided in 
Table 7. Additionally, the molecular structures of all substances used are shown in Figure 13. 
 
Table 7: 
Drug and inhibitor concentrations applied for combination growth assays. 
 
Substance Concentration 
Cisplatin - 0.25 µM 0.5 µM 1 µM 2.5 µM 5 µM 
Pemetrexed - 1 µM 5 µM 10 µM 50 µM 100 µM 
Trabectedin - 0.5 nM 1 nM 5 nM 10 nM 25 nM 
Gemcitabine - 1 nM 5 nM 10 nM 25 nM 50 nM 
Vinblastine - 0.5 nM 1 nM 2.5 nM 5 nM 10 nM 
PD166866 - 2.5 µM 10 µM 
SU5402 - 2.5 µM 10 µM 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
2.3.5. Radiation: 
Cells were irradiated with cobalt
to 10 Gy. Treatment was performed in combination with FGF2, PD166866 and the dnFGFR1 
adenovirus and evaluated by viability assays. 
the first treatment and all experiments were done in 5 replicates.
2 x 103 cells per well were seeded in 96
containing 10% FCS. Treatment was started on the next day, using three different 
approaches: 
1) Radiation (2 Gy) – 24 h 
2) Treatment – 24 h –
3) Treatment – 24 h –
For treatment with FGF2 and PD166866, 100 µl of 
concentration were added, resulting in a final concentration of 10 ng/ml FGF2 and 2.5 and 
10 µM PD166866, respectively. In case of adenoviral transduction, viral suspension was 
added at MOI 10 for the Ad-dnFGFR1 and MOI 3 fo
in comparable percentages of GFP
hours, the virus particles were washed away by rinsing 3 times with PBS and replaced by 
normal growth medium. Efficiency o
microscope.  
All experiments were compared to
Figure 13: 
Molecular structures of the drugs used for combination experiments with FGFR inhibitors.
 
-60 rays (Theratron 780, MDS Nordion) in a range from 0.5 
Generally, data were evaluated 72 
 
-well microtiter plates in a volume of 100 µl medium 
– Treatment – 48 h – Evaluation 
 Radiation (2 Gy) – 48 h – Evaluation 
 Radiation (1 Gy) – 24 h – Radiation (1 Gy) – 
medium containing 2
r the Ad-GFP control construct, resulting 
-expressing transduced cells. After an incubation time of 7 
f transduction was checked under the fluorescence 
 equally treated, but non-irradiated controls.
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34 | P a g e  
 
2.4. Expression analysis / RNA level: 
 
2.4.1. RNA isolation: 
RNA was isolated from a nearly confluent 6-well plate or from a T25 flask using TRIzol 
reagent (Invitrogen). Medium was discarded and cells were washed once with PBS. Then, 3 
ml/T25 or 1 ml/6-well TRIzol were added and cells were scraped off into suspension, 
incubated 5 minutes at room temperature and transferred into 1.5 ml Eppendorf tubes (1 ml 
per tube). Tubes were stored at -80°C, if required.  
Subsequently (or in case of storage after thawing) 200 µl chloroform were added and mixed 
by inverting or vortexing the tubes. Then, samples were centrifuged for 20 minutes at 13000 
g at 4°C. The upper, colorless aqueous phase was gently transferred into a new tube and 500 
µl isopropanol were added. Tubes were vortexed and either incubated 10 minutes at room 
temperature or stored at -20°C for 1 to 3 hours, allowing the RNA to precipitate. Afterwards, 
samples were again centrifuged for 10 minutes at 13000 g at 4°C. Supernatant was discarded 
and pellet was washed by adding 1 ml 75% ethanol and vortexing. After centrifugation for 5 
minutes at 13000 g at 4°C, supernatant was discarded and the pellet air-dried. Finally, RNA 
was dissolved in 15 µl nuclease-free ddH2O at 65°C for 5 minutes and then stored at -80°C. 
RNA concentration and purity were determined by measuring the optical density at 260 nm 
(OD260) on a NanoDrop 1000 spectrophotometer (Peqlab) and the quality was checked using 
agarose gel electrophoresis. 
 
2.4.2. Synthesis of cDNA: 
For the reverse transcriptase reaction, 2 µg RNA were diluted in 13 µl ddH2O and heated up 
to 70°C for 10 minutes for denaturation.  After cooling down on ice, 7 µl cDNA Master-Mix 
were added and samples incubated at 42°C for 1 hour. The reaction was stopped by 
denaturating the enzyme at 70°C for 10 minutes. Finally, samples were diluted 1:1 by adding 
20 µl ddH2O and then stored at -20°C.  
 
1 x cDNA Master Mix (7µl total volume): 
4 µl M-MLV RT buffer (5 x, Fermentas) 
0.5 µl Random Hexamer Primers (0.5 µg/µg, Fermentas) 
1 µl dNTPs (10 mM, Fermentas) 
1 µl Reverse Transcriptase (200 U/µl, Fermentas) 
0.5 µl RiboLock RNase-Inhibitor (40 U/µl, Fermentas) 
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2.4.3. Reverse Transcription Polymerase Chain Reaction (RT-PCR): 
For specific amplification of a gene of interest, RT-PCRs were performed in 200 µl PCR tubes 
in a MyCycler Thermal Cycler (Bio-Rad). For that purpose, 1 µl cDNA was mixed with 24 µl 
PCR-Master Mix containing the appropriate primers for the gene of interest to be amplified. 
PCR programs were conducted according to the required conditions for the respective 
primers. The correct size of the amplified PCR products was verified using agarose gel 
electrophoresis. The PCR standard program, all used primers, their sequence, optimal 
annealing temperature and size of amplified product are listed in tables 8, 9 and 10. 
 
Table 8: 
Standard RT-PCR conditions. 
 
 
Temperature (°C) Time (minutes) Repetitions 
Initial Denaturation 94°C 03:00 1 x 
Denaturation 94°C 00:50 
40 x Annealing 53°C – 61°C 00:50 
Elongation 72°C 00:50 
Final Elonagation 72°C 02:00 1 x 
 
Table 9: 
List of FGF primers used in RT-PCR. 
 
Direction Target Primer Sequence 
Annealing 
Temperature 
(°C) 
PCR Product Size 
(bp) 
sense FGF1 GAAGCCCAAACTCCTCTACTG 56 260 
antisense 
 
TGTTGTAATGGTTCTCCTCCA 
  
sense FGF2 CTGTACTGCAAAAACGGG 56 349 
antisense 
 
AAAGTATAGCTTTCTGCC 
  
sense FGF 3 CGATGCCACGATGGGCCTAATCTGG 56 530 
antisense 
 
TTCTGTGTGCGGCGGGTCTTGAAGC 
  
sense FGF 4 ACTACCTGCTGGGCATCAAGCGG 56 326 
antisense 
 
TCTTGCTCAGGGCGATGAACATGC 
  
sense FGF 5 CCCGGATGGCAAAGTCAATGG 61 266 
antisense 
 
TTCAGGGCAACATACCACTCCCG 
  
sense FGF 6 AACGTGGGCATCGGCTTTCACCTCC 56 301 
antisense 
 
CCCGCTTTACCCGTCATTTGC 
  
sense FGF 7 CTTTGCTCTACAGATCATGCTTTC 60 541 
antisense 
 
TTGCCATAGGAAGAAAGTGGGCTG 
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sense FGF 8 TGAGCTGCCTGCTGTTGCACTTG 60 301 
antisense 
 
CTTGGCGATCAGCTTCCCCTTCTTG 
  
sense FGF 9 AATGTGCCCGTGTTGCCGGTG 56 490 
antisense 
 
AATTTCTGGTGCCGTTTAGTCCTAGTCCCT 
  
sense FGF 10 CCAAGAAGGAGAACTGCC 54 243 
antisense 
 
CCATTCAATGCCACATAC 
  
sense FGF 11 GCTCCTTCACCCACTTCAAC 53 283 
antisense 
 
GCTGCCTTGGTCTTCTTAACTC 
  
sense FGF 12 GGACGAAAACAGCGACTACAC 53 269 
antisense 
 
TCCCCTTCATAATTTGACCTTC 
  
sense FGF 13 ACCGTCAGCAGCAGTCAG 53 222 
antisense 
 
TCAGCACGCCAGAGACAC 
  
sense FGF 17 TGCTGCCCAACCTCACTC 53 361 
antisense 
 
TCTTTGCTCTTCCCGCTG 
  
sense FGF 18 ACTTGCCTGTGTTTACACTTCC 53 379 
antisense 
 
CCAGAACCTTCTCGATGAAC 
  
sense FGF19 n/a 53 350 
antisense 
 
n/a 
  
sense FGF20 ACAGCCTCTTCGGTATCT 56 316 
antisense 
 
GGATCCACTGGTCTAGGTAA 
  
sense FGF21 TTCTGTGCTGGCTGGTCTT 56 264 
antisense 
 
CACAGGAACCTGGATGTCTTG 
  
 
 
 
Table 10: 
List of FGFR splice variant primers used in RT-PCR. 
 
Direction/Designation Target Primer Sequence 
Annealing 
Temperature (°C) 
PCR Product Size 
(bp) 
sense 5 FGFR1 IIIb+c TCCAGTGGCTAAAGCACATC 56 376 
antisense 6 
 
ATCTGGCTGTGGAAGTCACTC 
  
sense 5 FGFR1 IIIb TCCAGTGGCTAAAGCACATC 56 125 
antisense 7 
 
CCGCATCCGAGCTATTAATC 
  
sense 3 FGFR1 IIIc GACAAAGAGATGGAGGTGCT 56 801 
antisense 4 
 
GTTGTAGCAGTATTCCAGCC 
  
sense 5 
 
TCCAGTGGCTAAAGCACATC 56 170 
antisense 8 
 
CGCCAAGCACGTATACTC 
  
sense 11 FGFR2 IIIb+c AACGGGAAGGAGTTTAAGCAG 56 598, 601, 607 
antisense 14 
 
CCACCATACAGGCGATTAAG 
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sense11 FGFR2 IIIb+c AACGGGAAGGAGTTTAAGCAG 56 417 
antisense 13 
 
CTCGGTCACATTGAACAGAG 
  
sense11 FGFR2 IIIc AACGGGAAGGAGTTTAAGCAG 56 504, 513 
antisense 12 
 
TGGCAGAACTGTCAACCATGC 
  
sense 17a FGFR3 IIIb+c AACGGCAGGGAGTTCCGCGGC 56 720 
antisense 18 
 
GGACGCGTTGGACTCCAGGG 
  
sense17a FGFR3 IIIb AACGGCAGGGAGTTCCGCGGC 56 429 
antisense 19 
 
CCCGTCCCGCTCCGACACATTG 
  
sense17a FGFR3 IIIc AACGGCAGGGAGTTCCGCGGC 56 435 
antisense 20 
 
CCCGGCGTCCTCAAAGGTG 
  
sense 21 FGFR4 Iso1-3 n/a 56 597 
antisense 22 
 
n/a 
  
 
 
2.4.4. Agarose gel electrophoresis: 
Nucleic acids (RNA, DNA) were separated by agarose gel electrophoresis (GenXpress) 
according to their length (bp). 1 kb or 100 bp DNA ladders (Fermentas) were used for size 
determination, depending on the expected fragment sizes. 
In order to analyze the size of amplified PCR products or to check the quality of isolated RNA, 
samples were mixed with the appropriate amount of 6 x loading dye and then loaded onto 
gels consisting of 1-2% (w/v) agarose (StarLab) in 0.5 x or 1 x TBE buffer. RNA samples were 
previously mixed 1:1 with 2 x Urea-buffer and denaturated at 70°C for 10 minutes. 
Depending on the fragment size, gels were run at 90 V for 30-45 minutes. Bands were 
stained by Vistra Green (GE Healthcare), a dye which becomes fluorescent when binding to 
nucleic acids, and visualized by a Typhoon Trio FluorImager (GE Healthcare). 
 
1 x TBE (Tris-borate-EDTA) buffer: 
 
10.8 g/l Trizma base (Sigma) 
5.5 g/l boric acid (Sigma) 
4 ml/l 0.5M EDTA, pH = 8.0 
 
 
2 x Urea-buffer: 
 
2 x TBE 
7 M urea 
15% glycerol 
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6 x Loading buffer: 
 
333 μl/ml 6 x Loading Dye (Fermentas) 
250 μl/ml 80% glycerol (Merck) 
66.5 μl/ml 0.5 M EDTA 
0.5 μl/ml 10000 x Vistra Green (GE Healthcare) 
 
 
2.4.5. Quantitative real-time Polymerase Chain Reaction (qRT-PCR):  
To obtain a semi-quantitative analysis of the transcript levels of the genes of interest, qRT-
PCRs were performed. 1 µl cDNA was transferred in a MicroAmp Optical 96-well Reaction 
Plate (Applied Biosystems) and mixed with 11 µl TaqMan qRT-PCR Master Mix, containing 
the appropriate TaqMan probe, resulting in a final volume of 12 µl. All preparations were 
done on ice and in duplicates. PCR was performed in an ABI Prism 7000 SDS Thermocycler 
(Applied Biosystems) and fluorescence was measured after every cycle. The housekeeping 
genes GAPDH and β-actin were used as references for normalization. PCR standard 
conditions and TaqMan probes used are listed below in Table 11 and 12. Additionally, PCR 
products were verified by agarose gel electrophoresis. 
 
TaqMan qRT-PCR Master Mix: 
 
9.25 µl ddH2O 
12.5 µl 2 x Maxima Probe qRT-PCR Master-Mix (Fermentas) 
1.25 µl TaqMan probe (applied Biosystems) 
 
Table 11: 
Standard conditions for TaqMan quantitative RT-PCR. 
 
 
Temperature (°C) Time (minutes) Repetitions 
Stage 1 50°C 02:00 1 x 
Stage 2 95°C 10:00 1 x 
Stage 3 
95°C 00:15 
40 x 
60°C 01:00 
 
Table 12: 
TaqMan probes used for expression analysis via qRT-PCRs. 
 
Target Assay ID 
FGFR1 Hs00915135 m1 
FGFR2 Hs01552926 m1 
FGFR3 Hs00179829 m1 
FGFR4 Hs00608751 g1 
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FGF1 Hs01092738 m1 
FGF2 Hs00960934 m1 
FGF3 Hs00173742 m1 
FGF5 Hs00170454 m1 
FGF9 Hs00181829 m1 
FGF18 Hs00826077 m1 
FGF19 Hs00391591 m1 
EGFR Hs01076078 m1 
VEGFA Hs00900055 m1 
β-actin Hs99999903 m1 
GAPDH Hs99999905 m1 
 
2.5. Protein analysis: 
 
2.5.1.  Protein isolation: 
For total protein isolation, 5 x 105 cells were seeded in a 6-well plate in 2 ml medium and 
incubated over night. Treatment was added on the next day. After distinct time periods (15 
minutes to 24 hours), dishes were put on ice and medium was discarded and cells were 
carefully washed with ice-cold PBS. 1 ml PBS was added and cells were scraped off into 
suspension and then transferred into a 1.5 ml Eppendorf tube. 
After centrifugation at 200 g for 5 minutes at 4°C, supernatant was discarded and the pellet 
was resuspended in 60 µl Lysis Buffer II. The suspension was sonicated for 5 minutes and 
then again centrifuged at 12000 g for 5 minutes at 4°C. The supernatant, containing the 
proteins, was transferred into a new tube and stored at -20°C. 
Protein concentration was determined by Bradford Protein Assay (Bio Rad) according to the 
manufacturer’s manual. 
 
Lysis Buffer II: 
1 mM EDTA 
150 mM NaCl 
0.5 mM Na3VO4 
1.5 mM MgCl2 
10% glycerol 
50 mM HEPES 
10 mM NaF 
1% Triton X-100 
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2.5.2. SDS-PAGE: 
Proteins were separated on polyacrylamide gels according to their molecular weight (kDa). 
For each sample, 15 – 30 µg protein were diluted in a volume of 20 µl ddH2O and mixed with 
5 µl 5 x reducing Laemmli buffer. After 5 minutes denaturation at 100°C, samples were 
spinned down and loaded on a discontinuous polyacrylamide gel consisting of a 10% 
separating gel and a 5% stacking gel.  
Additionally, to avoid leakage of the liquid gel, a thin layer of sealing gel was placed at the 
bottom. A Page Ruler Plus Prestained Protein Ladder (Fermentas) was used as maker. Gel 
electrophoresis was performed in a Mini Protean 3 system. The gel was run in SDS-Running 
buffer at 60 V until the blue tracking dye came up to the end of the stacking gel, and then at 
130 V until the front reached the sealing gel. 
5 x reducing Laemmli Buffer: 
 
300 nM Tris, pH = 6.8 
60% (w/v) glycerol 
10% SDS 
0.025% bromphenolblue 
7% β-mercaptoethanol (Aldrich) 
 
 
Stacking gel: (5% PAA, 5 ml) 
 
3.6 ml ddH2O 
635 µl 0.5 M Tris-HCl, pH = 6.8 
100 µl 10% SDS 
625 µl 30% Acrylamid/Bis; 29:1 (Bio-Rad) 
50 µl 10% APS (Merck) 
7.5 µl TEMED (Amresco) 
 
 
Separating gel: (10% PAA, 15 ml) 
 
5.8 ml ddH2O 
3.75 ml 1.6 M Tris-HCl, pH = 8.8 
300 µl 10% SDS 
5.025 ml 30% Acrylamid/Bis; 29:1 (Bio-Rad) 
37.5 µl 10% APS (Merck) 
25 µl TEMED (Amresco) 
 
 
Sealing gel: 
 
1 ml 30% Acrylamid/Bis; 29:1 (Bio-Rad) 
10 µl 10% APS (Merck) 
10 µl TEMED (Amresco) 
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SDS-Running Buffer: 
 
25 mM Tris base 
192 mM glycin 
0.1% SDS 
 
2.5.3. Western Blot: 
In order to transfer the separated proteins from the polyacrylamide gel to a solid membrane, 
proteins were blotted onto a PVDF-Membrane (Hypond-P, GE Healthcare) using a Mini 
Protean 3 System according to the manufacturer’s instructions (Gallagher et al. 2008). 
Before usage, the PVDF membrane was activated with methanol. The protein transfer was 
performed in Towbin Transfer buffer in a 4°C fridge over night at 18 V or 1 hour at 400 mA. 
To check the quality of the transfer, the membrane was stained with Ponceau S solution for 
about 30 minutes. The background was removed by rinsing with ddH2O and then the 
membrane was air-dried. After documentation of the staining using a scanner or a 
photocopier, the membrane was again activated with methanol and then blocked in 5% skim 
milk powder (Fluka) in TBST (TBS containing 0.1% Tween) for at least 1 hour on a shaker at 
room temperature. The milk was removed by washing quickly with TBST ant then the 
membrane was incubated in the primary antibody solution over night at 4°C. A complete list 
of the used antibodies, their dilutions and diluents is shown in Table 13 below. As loading 
control, the housekeeping gene β-actin was used. 
The next day, membranes were washed 3 x 10 minutes with TBST and then incubated in the 
secondary antibody solution (Table 14) for 1-2 hours at room temperature. After again 
washing 3 x 10 minutes with TBST and 1 x 10 minutes with TBS, antibody binding was 
visualized on x-ray films (Thermo Scientific) by using Immun-Star WesternC Kit (Bio-Rad) as 
recommended in the manual. Exposure time to the x-ray film was adapted as necessary to 
get evaluable signals and ranged between 1 second and 1 hour.  
After film development, membranes were washed with TBST, air-dried and stored at 4°C. 
Membranes were used several times. 
Ponceau S Solution: 
 
0.5 g/l Ponceau S (Sigma) 
1 ml/l glacial acetic acid 
 
Towbin Transfer buffer: 
 
13.39 g/l glycine 
3.03 g/l Tris base 
50 ml/l methanol 
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TBS (Tris-buffered saline): 
 
8 g/l NaCl 
0.2 g/l KCl 
3 g/l Tris base 
HCl – pH 7.4 
 
      
 
Table 13: 
List of primary antibodies used for western blotting. 
 
Antibody Dilution Diluent Size of target (kDa) Assay ID 
Rabbit anti- Stat3 1:1000 3% BSA in TBST 80 kDa Cell Signalling 
Rabbit anti- pStat3 1:1000 3% BSA in TBST 80 kDa Cell Signalling 
Rabbit anti- Erk 1/2 1:1000 3% BSA in TBST 42/44 kDa Cell Signalling, 9102 
Rabbit anti- pErk 1:1000 3% BSA in TBST 42/44 kDa Cell Signalling, 9101 
Rabbit anti- S6 1:1000 3% BSA in TBST 30 kDa Cell Signalling, 2217 
Rabbit anti- pS6 1:1000 3% BSA in TBST 30 kDa Cell Signalling, 2215 
Mouse anti- β-actin 1:8000 3% BSA in TBST 42 kDa Sigma 
 
 
Table 14: 
List of secondary antibodies used for western blotting. 
 
Antibody Dilution Diluent Supplier 
Polyclonal Goat anti-Rabbit 
Immunoglobulins/HRP 
1:10000 5% milk in TBST Dako 
Anti-Mouse HRP 1:10000 5% milk in TBST Dako 
 
2.5.4. Immunofluorescence: 
For fluorescence-based immunostaining, 1.5 x 104 cells were seeded in a Millicell EZ 8-well 
chamber slide (Millipore) in a volume of 100 µl growth medium. On the next day, the 
medium was removed and cells were washed with cold PBS. Then, slides were transferred to 
a wet chamber and cells were fixed with either paraformaldehyde (PFA) or methanol and 
acetone.  
The method of choice when cell membranes have to be visualized is paraformaldehyde (PFA) 
fixation. Therefore, cells were fixed with 50 µl per well 4% PFA for 15 minutes and washed 
twice for 3 minutes with PBS. For membrane permeabilization, cells were incubated for 10 
minutes with PBST (PBS + 0.1% Tween) containing 0.25% Triton X-100 and again washed 3 x 
3 minutes with PBS.  
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Another approach to fix cells is by methanol and acetone. Cells were incubated 10 minutes 
with 200 µl cold methanol/acetone (1:1) in a freezer at -20°C and then washed with cold 
PBS. 
Unspecific binding sites were blocked with PBST containing 1% BSA for 30 minutes. 
Afterwards, 50 µl of the primary antibody solution were added and incubated for 1 hour. 
After 3 x 3 minutes washing with PBS 50 µl of the fluorophore-conjugated (FITC, Cy3) 
secondary antibody dilution were added and incubated for 1 hour in the dark. All primary 
and secondary antibodies used in this study and their dilutions are listed in Table 15. 
Afterwards, slides were washed 3 x 5 minutes in PBS and cells were embedded in 
Vectashield Hard Set mounting medium (Vector) containing 1.5 µg/ml DAPI. After a few 
hours, slides were sealed with nail polish and stored in the dark at 4°C.  
As negative control, cells were only incubated with the secondary antibody. The staining was 
visualized on a Zeiss LSM 700 confocal microscope and pictures were taken using Zen 2000 
software. 
 
Table 15: 
List of primary and secondary antibodies used for immunofluorescence. 
 
Antibody Dilution Diluent Assay ID 
Rabbit anti- FGF2 1:50 1% BSA in PBST Santa Cruz, Sc-79 
Goat anti- FGF18 1:50 1% BSA in PBST Santa Cruz C16, Sc-16830 
Rabbit anti- pFGFR1 pY653/654 1:50 1% BSA in PBST Thermo Scientific, PA5-12594 
anti- Rabbit, FITC labeled 1:500 1% BSA in PBST Sigma 
anti- Goat, Cy3 labeled 1:500 1% BSA in PBST Sigma 
 
 
2.5.5.  Immunohistochemistry: 
Immunohistochemistry provides the visualization of proteins of interest within tissue 
samples via antibodies that specifically bind their targets within the tissue. Detection is 
based on enzymes, such as peroxidase, that catalyze a color-producing reaction after adding 
an appropriate substrate. 
For deparaffination and rehydration, tissue samples were incubated in a drying oven at 65°C 
for 10 minutes, followed by a series of washing steps (2 x 1 minute) in different reagents, 
xylol, 100% ethanol, 70% ethanol and ddH2O. 
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Then, slides were incubated for 10 minutes in 0.3% H2O2 in PBS, washed 2 x 3 minutes in 
PBS, heated in a pressure cooker for 2 minutes at 1.5 bar in 10 mmol/l citrate buffer (pH 6.0) 
for epitope retrieval and allowed to cool down for 15 minutes. All following incubation steps 
were performed in a wet chamber. 
From this step, the procedure differed depending on the animal-source of the primary 
antibody used. All used antibodies are listed below in Table 16. For rabbit-derived primary 
antibodies, the specific antibody binding was detected via the UltraVision LP Detection 
System (Thermo Scientific) according to the manufacturer’s recommendations.  
Due to the application of goat serum in the UltraVision LP protocol, goat-derived primary 
antibodies require an alternative detection system. Unspecific binding sites were blocked for 
10 minutes with 10% normal horse serum (Vector) in PBST (PBS containing 0.1% Tween). 
After incubation with the primary antibody, which was also diluted in this solution, slides 
were washed 2 x 3 minutes with PBST. The biotinylated secondary antibody (Rabbit anti goat 
Immunoglobulins/Biotin, Dako) was also diluted in 10% normal horse serum in PBST and 
incubated for 30 minutes. After 2 x 3 minutes washing with PBST, samples were incubated 
with Vectastain ABC-Kit (Vector) for another 30 minutes and finally again washed 2 x 3 
minutes with PBST. 
Color development was performed by DAB, generating a brown coloration when oxidized 
after reaction of the horseradish peroxidase (HRP) with its substrate, H2O2. DAB/Chromogen 
solution was mixed 1:50 with Substrate Buffer (Liqud DAB+ Substrate Chromogen System, 
Dako) and slides were incubated for 1-10 minutes. Reaction was stopped with ddH2O. Nuclei 
were counterstained in blue with hematoxylin (Gill III, Merck). Then, samples were 
dehydrated by consecutively immersing twice through another series of reagents (70% 
ethanol, 80% ethanol, 95% ethanol, 100% ethanol, EBE) and embedded in entellan (Merck). 
 
Table 16: 
Antibodies used for immunohistochemical tissue staining. 
 
Antibody Dilution Diluent 
Incubation 
time 
Assay ID 
Rabbit anti- FGF2 1:2000 1% goat serum in PBST 1 h Santa Cruz, Sc-79 
Goat anti- FGF18 1:200 10% horse serum in PBST o/n Santa Cruz C16, Sc-16830 
Rabbit anti- pFGFR1 
pY653/654 
1:50 1% goat serum in PBST o/n Thermo Scientific, PA5-12594 
Rabbit anti- goat, biotinylated 1:500 10% horse serum in PBST 30 min Dako 
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2.6. Cell growth and viability: 
 
2.6.1.  MTT-Assay: 
The impact of drugs, tyrosine kinase inhibitors and genetic constructs on cell proliferation 
and cell viability was evaluated by MTT-Assay (Biomedica Austria, MTT kit EZ4U). This 
colorimetric assay is based on the enzymatic reduction of 3-(4,5-Dimethylthiazol-2-yl)-2,5-
diphenyl-tetrazolium bromide; MTT) to the orange colored formazan derivative.  
Since this process requires active and functional mitochondrial reductase enzymes, only 
viable cells lead to an orange coloration, while dead cells remain uncolored.   
 
2 x 103 cells were seeded in a 96-well plate in 100 µl medium and allowed to recover over 
night. Then, another 100 µl medium containing the treatment (2 x stock or, in case of 
combinations, 50 µl 4 x stock of each) were added. After 72 hours, the medium was 
aspirated and replaced by 100 µl fresh medium, containing 10% EZ4U reagent. The mixture 
was incubated 1-3 hours to give rise to the coloration and absorption was measured at 450 
nm and 620 nm as reference using a SynergyHT spectrophotometer (BioTEK).  
The ΔOD ratio between the untreated control and treated cells indicates the cytotoxicity of 
drugs, expressed as IC50 values (half maximal inhibitory concentration) and calculated from 
dose response curves. Experiments were performed in 3-5 replicates. Furthermore, 
Combination indices (CI values) were calculated. 
 
2.6.2.  Clonogenic Assay: 
Another approach to investigate the effects of drugs on cells is by determining the capacity 
of colony formation. Therefore, 1 x 103 cells (1 x 104 in case of the I2 cell line) were seeded in 
a 6-well plate. After 24 hours cells were treated with either stimulating/inhibiting agents, 
drugs or adenoviral constructs and allowed to grow for 10-14 days. Experiments were done 
in duplicates or triplicates and, as control, cells were vehicle treated. Afterwards, cells were 
washed with PBS, fixed with 1 ml methanol/acetic acid (3:1) for 20-30 minutes, washed with 
PBS and stained with crystal violet (10% CV in ethanol, 1:1000 in PBS) for 2 hours. Finally, to 
remove the excessive CV, plates were washed with ddH2O and air-dried over night. 
After pictures were taken for further investigation (e.g. counting of colonies), the colonies 
were destained with 2% SDS for a few hours. The solution was then transferred into a 96-
well microtiter-plate and absorption at 562 nm, which is proportional to the number/size of 
stained colonies, was photometrically measured in duplicates using a SynergyHT plate reader 
(BioTEK). 
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Figure 14: 
M38K cells cells stained with Hoechst 22538 
(blue) and propidium iodite (red). A phase 
contrast micrograph is also shown for better 
orientation. 
2.6.3. Hoechst-PI-Staining: 
Hoechst 33528 is a DNA intercalating dye that binds to 
the minor DNA groove. When exited with UV-light at 
465 nm, it produces a bright blue fluorescence and is 
used to visualize different states of the nucleus during 
mitosis or apoptosis. PI is another DNA intercalating dye 
that produces red fluorescence when excited with 488 
nm light. In contrast to Hoechst, which is able to pass 
through intact or fixed membranes and stains all nuclei, 
PI is generally excluded from viable cells, and therefore a 
marker for apoptosis and necrosis. 
100 x Hoechst/PI dye: 
 
1 x PBS 
500 µg/ml Hoechst 33258 
200 µg/ml propidium iodite 
 
 
To distinguish between viable and dead cells (necrotic or 
apoptotic), cells were stained with Hoechst 33258 and 
propidium iodite (PI). Hoechst/PI dye was added 1:100 
and incubated for at least 1 hour. Then pictures at 
appropriate wavelengths were taken. For representative 
pictures of Hoechts/PI-stained cells, see Figure 14. 
 
2.6.4. Spheroid Formation Assay: 
In this assay, the dependence of three-dimensional growth and spheroid formation on FGF-
mediated signals was analyzed.  
For that purpose, 2 x 104 cells were seeded in low attachment 24-well plates and maintained 
under different medium conditions, on the one hand in FGF-free SCM and on the other hand 
in SCM containing 10 µM PD166866. As control, cells were grown in normal SCM (containing 
20 ng/ml FGF2). Spheroid formation was checked daily by microscopy and pictures were 
taken on days 1, 3, 7 and 10. According to these pictures, the mean spheroid number, mean 
spheroid size and therefore the spheroid formation capacity for each medium condition 
were calculated. Spheroids with a diameter of more than 100 µm were considered as proper 
spheres and included into evaluation. All experiments were performed in triplicates. 
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After 10 days, MTT assays were performed either by directly adding the EZ4U reagent and, 
after the incubation time, transferring the medium into 96-well plates for the photometric 
measurement, or by carefully transferring the spheroids first into 96-well plates, followed by 
addition of the EZ4U reagent and photometric measurement.  
Additionally, to visualize the distribution of viable and dead cells in spheres, cells were 
stained with Hoechst/PI and pictures were taken. 
 
2.7. Cell migration & invasion: 
 
2.7.1. Platypus assay: 
Cell migration was monitored by Platypus assay. (Oris Cell Migration Assembly Kit - FLEX, 
Platypus Technologies). 2 x 104 cells in a volume of 100 µl medium were seeded into a 96-
well plate, each well containing the Oris Seeding Stoppers as suggested in the 
manufacturer’s manual. The following day, cells were stained with CellTracker Green CMFDA 
(1:5000, Invitrogen) for 1 hour. Then, stoppers were removed, medium was discarded, cells 
were washed twice with 150 µl PBS and 200 µl fresh medium containing the treatment were 
added. From now on (t = 0 hours), pictures were taken twice a day using the Oris Detection 
Mask and a fluorescence microscope. 
Experiments were performed in triplicates and evaluated by calculating the covered area 
(mm2 x 100) and the percentage of the covered area at each time point using Image J 
software. 
 
2.7.2. Transwell Migration Assay: 
Another method to investigate cell migration is the Transwell Migration Assay (BD Falcon). 4 
x 104 cells were seeded in a volume of 200 µl standard growth medium containing 10% FCS 
on the porous membrane (8 µm diameter of pores) of a 24-well format transwell-chamber 
(BD Falcon) and another 800 µl medium were added into the 24-well plate resulting in a 
total volume of 1 ml. Cells were incubated for 4 hours to attach and then the treatment was 
added to the medium on both sides of the membrane. Cells were allowed to transmigrate 
through the membrane for 24 hours. Then, the transwell-chamber was removed, cells were 
washed with PBS and 1ml of fresh medium was added. Plates were incubated another 7-10 
days, until the cells that had trans-migrated through the porous membrane formed colonies. 
Finally, cells were stained with crystal violet, pictures were taken, the dye was solubilized in 
2% SDS and clonogenicity was evaluated as in the clonogenic assay. 
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2.7.3. Transwell Invasion Assay: 
In order to check the invasion ability of the cells, the conventional Transwell Migration Assay 
(BD Falcon) was upgraded to an Invasion Assay. The principle is the same as in the Migration 
Assay, but the porous membrane is coated with a layer of collagen, so the cells have to 
transmigrate through the collagen layer as well as through the pores. First of all the 
transwell chambers were inserted into the 24-well plate, containing 800 µl growth medium. 
30 µl of collagen solution (1:12.5 in PBS, Sigma) were dropped on the top of the membrane 
and incubated over night at 4°C. The next day, 4 x 104 cells were seeded into the transwell 
chamber and immediately, treatment was added. After 72 hours incubation time, transwell 
chambers were removed and medium was changed to normal growth medium. Cells were 
allowed to form colonies for 7 days and then evaluated by CV staining. 
 
2.8. Statistical analysis: 
 
Unless stated otherwise, data are presented as means and SD of at least three experiments. 
Statistical significance between treatments was analyzed with GraphPad Prism 5.0 software 
(GraphPad Software Inc.) using Student’s t test or one-way ANOVA combined with Turkey’s 
Multiple Comparison Test for comparison of two or multiple groups, respectively. In all 
cases, p ≤ 0.05 was considered statistically significant (labeled as *).  P-values from 0.001 to 
0.01 were regarded as very significant (**) and those below 0.001 as highly significant (***). 
IC50 values were also calculated using GraphPad Prism 5.0 software. 
Combination index (CI) values indicating additive (0.9 < CI < 1.1), antagonistic (CI > 1.1) or 
synergistic (CI  < 0.9) drug interaction were calculated by the method of Chou and Talalay  
(Chou and Talalay 1984) using CalcuSyn Software (Biosoft, Cambridge, UK). 
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3. RESULTS: 
 
3.1. Expression analysis of FGF receptors and ligands: 
 
3.1.1. RT-PCR & qRT-PCR: 
To elucidate which FGFs and FGFRs are expressed in mesothelioma cells, our panel of 
mesothelioma cell lines was screened by conventional RT-PCR and TaqMan qRT-PCR.  
Among the receptors, FGFR1 was the dominant receptor expressed, followed by FGFR4, 
which showed a higher degree of variability between different cell lines (Figure 15). 
Concerning the FGFR IIIb and IIIc splice variants, we found no apparent domination of one 
isotype, as shown in Table 17. With respect to the FGF ligands, expression of FGF2 and 
FGF18 was especially prominent, but also for FGF1, FGF5, FGF9 and FGF19 high transcript 
levels were detected in some cell lines by qRT-PCR (Figure 15).  In contrast, as shown in 
Table 18, other FGFs were expressed at more moderate levels or were even undetectable by 
PCR, such as FGF3 or FGF4. 
In general, the results from quantitative analysis correlated quite well with the band 
intensities observed in conventional RT-PCR, except for FGF5 and FGF9, which were not 
detectable by conventional PCR. 
In addition to the FGF and FGFR gene family, the expression of the Epidermal Growth Factor 
Receptor (EGFR) and Vascular Endothelial Growth Factor A (VEGFA) was also evaluated by 
qRT-PCR. As shown in Figure 15, both, the EGFR and VEGFA were highly expressed in all cell 
lines tested, the EGFR comparable to the FGFR1 and VEGFA much higher than the FGF 
ligands. 
 
 
 
 
 
 
 
 
 
 
Figure 15: 
Relative expression of selected FGFs and their receptors, including also VEGFA and EGFR, investigated by 
qRT-PCR. Results are shown as 2
-ΔCT
*10000 values. The housekeeping gene GAPDH was used as reference. 
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Table 17: 
Expression analysis of FGF-Receptors, including different splice variants, by standard Reverse Transcription 
Polymerase Chain Reaction (RT-PCR). Evaluation was categorized as “not detectable” (-), “detectable” (+) and 
“highly expressed” (++). 
 
 
Met5a SPC111 SPC212 CRL5820 p31 p31 res1.2 I2 M38K VMC6 VMC20 
FGFR1 IIIb ++ ++ ++ ++ ++ ++ ++ ++ ++ ++ 
FGFR1 IIIc + + + + + + + + + + 
FGFR2 IIIb - + + + + - - + + - 
FGFR2 IIIc ++ ++ + ++ ++ - ++ - - - 
FGFR3 IIIb ++ ++ ++ ++ + + ++ ++ ++ + 
FGFR3 IIIc - ++ ++ ++ + ++ ++ ++ + + 
FGFR4 - - - - ++ ++ ++ + - + 
 
 
Table 18: 
Expression analysis of FGFR-Ligands by standard Reverse Transcription Polymerase Chain Reaction (RT-PCR). 
Evaluation was categorized as “not detectable” (-), “detectable” (+) and “highly expressed” (++). 
 
 
Met5a SPC111 SPC212 CRL5820 p31 p31 res1.2 I2 M38K VMC6 VMC20 
FGF1 - + + - ++ ++ ++ - + ++ 
FGF2 ++ ++ ++ ++ ++ ++ ++ ++ + + 
FGF3 - - - - - - - - - - 
FGF4 - - - - - - - - - - 
FGF5 - - + - + - - - - - 
FGF6 - - - - - - - - - - 
FGF7 - - - - - - - - - - 
FGF8 - - - - - - - - - - 
FGF9 - - - - - - - - - - 
FGF10 - + - - - - - - - - 
FGF11 ++ ++ ++ ++ ++ ++ ++ ++ ++ ++ 
FGF12 + ++ + + - + - - - - 
FGF13 + + - ++ + ++ - ++ - - 
FGF17 - - - - + - ++ - - - 
FGF18 + ++ ++ ++ ++ ++ ++ + ++ ++ 
FGF19 - + - - ++ ++ ++ ++ ++ ++ 
FGF20 - + - - - ++ - - - - 
FGF21 ++ ++ ++ + + + ++ ++ + ++ 
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Compared to the Met5a control cell line, FGFR1 was overexpressed in 8 of 9 cell lines, 
whereas for FGFR3, much lower transcript levels were found. FGFR4 and FGFR2 showed a 
higher diversity in expression, but were also overexpressed in most of the cell lines tested. 
Expression of the FGF ligands differs between cell lines and EGFR and VEGFR are both highly 
overexpressed in relation to the control cell line (Figure16). 
Interestingly, for most of the genes remarkable differences between the P31 and the 
cisplatin-resistant derivative P31res1.2 cell line were found. 
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Figure 16: 
Relative expression of selected growth factors and receptors compared to the Met5a control cell line, analyzed by qRT-PCR. 
Ct-values are normalized to the housekeeping gene GAPDH. 
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3.1.2. pRGIIIc construct: 
Additionally to PCR, splicing of FGFR2 to the alternative IIIb and IIIc variants was evaluated 
using a genetic reporter construct. Transfection of the biphasic SPC111 cell line with pRGIIIc 
showed a general dominance of the FGFR2 IIIc splice var
PCR data shown in Table 17. For cells treated with FGF2 for 72 hours, no remarkable 
differences in splice variant expression compared to the untreated control cells were 
observed (Figure 17). 
 
 
 
 
3.1.3. Immunofluorescence:
Expression of the phosphorylated form of FGFR1 (Y653/654), FGF2 and FGF18 and their 
location within the cell was visualiz
contrast to FGF2 and FGF18, which seemed to be present mainly in vesicles or vesicle
intracellular structures, the phosphorylated FGFR1 was, as expected, located at the plasma 
membrane. In addition, a strong nuclear staining was found, the specificity of which is not 
yet clear. Negative controls indicated no unspecific binding of the secondary antibodies. 
Representative micrographs are shown in Figure 18.
Figure 17: 
Micrographs of SPC111 cells 48 hours after transfection with the pRGIIIc construct. FGF2 was added at 10 ng/ml.
 
iant, which is in concordance with 
 
ed by confocal immunofluorescence microscopy. 
 
In 
-like 
 
  
 
 
 
3.1.4. Immunohistochemistry:
Overexpression of FGF2, FGF18 and the phosphorylated FGFR1 (pFGFR1) in tumor cells 
compared to the normal surrounding tissue was verified by immunohistochemistry. 
Representative pictures are shown in Figure 19. Concerning the intracellular distribution of 
the proteins of interest, immunohistochemical 
performed on cell lines by immunoflourescence,
used. The pFGFR1 was basically located at the plasma membranes. Again, a nuclear s
was observed in addition to the expected membrane staining. In contrast, both ligands, FGF2 
and FGF18 were distributed all over the cytoplasm, especially FGF18 seemed to be mainly 
present in intracellular vesicular structures.
Generally looking at the tissue preparations, 
detectable only in tumor cells, 
the nuclear staining was also present in normal tissue.
Concerning FGF2, a strong difference between tumor
the one hand, highly positive sing
normal lung tissue, depicted in the upper right picture of Figure 19B
Figure 18: 
Representative immunoflourescence pictures of
pFGFR1. Nuclei (blue) were stained with DAPI. Cells were either fixed with paraformaldehyde (PFA) or methanol and 
acetone (met/ac). Negative controls were only exposed to se
 
 
staining correlated quite well with those 
 since the same primary antibodies were 
 
membranous pFGFR1 expression 
as shown in the lower right picture of Figure 19A
 
 and normal tissue was observed. On 
le tumor cells or small tumor islets were distributed within 
.  
 different mesothelioma cell lines showing expression of FGF2, FGF18 and 
condary antibodies. 
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taining 
was 
. However, 
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On the other hand, bigger, solid tumors containing al
were found. Epithelial tumor cells adjacent to luminal linings and structures, appeared to be 
polarized, expressing more FGF2 in their apical side (Lower right picture of Figure 19B).
FGF18 was also found to be highly e
negative surrounding tissue. Additionally, endothelial cells lining lymph vessels also 
appeared highly positive for FGF18.
In summary, 60 MPM tissue samples containing tumors of epitheloid, biphasic and 
sarcomatoid histotype were stained 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
most exclusively FGF2
xpressed in tumor cells in contrast to the completely 
  
and will be scored by pathologists. 
-positive cells 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 19: 
Micrographs of immunohistochemical tissue staining showing (A) pFGFR1, (B) FGF2 and (C) FGF18 in brown.
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3.2. FGF stimulation / FGFR inhibition:
 
3.2.1. Proliferation: 
In order to evaluate cell proliferation and viability of cells exposed to agents that stimulate 
or inhibit FGFR-mediated signaling, MTT
for 72 hours resulted in an increased viability of mesothelioma cells. This effect was most 
obvious at serum-free growth c
inhibition by PD166866 and S
strongly varied between subst
specific inhibitor PD166866 showed stronger effects than SU5402, which is considered to be 
active against multiple targets. IC
listed below in Table 19. 
 
 
 
 
 
 
 
 
 
 
 
 
Table 19: 
IC50 values of specific inhibitors after 72 hours treatment in medium with 10% FCS.
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Figure 20: 
(A) Effects of FGF2 (10 ng/ml) in serum
growth medium evaluated by MTT-assay 72 
hours after treatment.(B) Effects of SU5402 
and PD166866 on cell viability in medium 
containing 10% FCS 72 hours after treatment.
 
 
-assays were performed. Stimulation with 
onditions as shown in Figure 20A. In contrast, FGF receptor 
U5402 led to a dose-depended decrease of cell viability that 
ances and cell lines (Figure 20B). Surprisingly, the FGFR1
50 values of the two inhibitors for all tested cell lines are 
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 Additionally, clonogenic assays revealed similar and more pronounced effects of FGFR 
inhibitors on clone formation. Again, PD166866 showed much stronger effects than SU5402. 
This data was further confirmed by an alternative approach, a dnFGFR1 adenoviral c
which also resulted in a significant decrease of cell viability in most cell lines tested. 
Furthermore, FGFR inhibition by the tyrosine kinase inhibitors 
construct led to a reduction of size and number of cell clones.
adenovirus led to an increase of viability compared to the GFP control virus, which may be 
caused by a strong toxic effect of viral transduction itself.
summary of all cell lines tested are show
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 21: 
(A) Evaluation of clonogenic assays 11 days after treatment and (B) representative pictures. In case of SU5402 and 
PD166866 data were normalized to the 
was used as reference.  
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3.2.2. Three-dimensional growth 
Dependence on FGFR-mediated signaling was also investigated for a
three dimensional tumor growth
(VMC6) formed viable spheroids when cultured in ultra low attachment plates for a few 
days.  
PD166866 treatment resulted in a significant reduction of 
compared to the control, most of the cells were just accumulated in cell clumps
differences in spheroid size, shape and number were observed 
and FGF2-free conditions (Figure 22
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Figure 22: 
(A) Phase contrast pictures of SPC212 cell spheroids on day 7 grown in normal SCM, and FGF2
and after treatment with 10 µM PD166866. (B) Mean spheroid number and size of two cell
different growth conditions, evaluated from microscopic pictures after 7 days growth.
 
 
- spheroid formation: 
nchorage independent 
. 10 cell lines were tested and all of them except one 
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 Treatment with PD166866 also
by MTT assays, whereas differences between FGF
were less dramatic. Hoechst/PI
cultured cells only get necrotic in the middle of a sphere
PD166866 were almost completely 
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Figure 23: 
Viability of MPM spheroids, determined by Hoechst/PI staining (A) and MTT assay (B) 10 days 
after treatment. Data were normalized to control cells grown in normal SCM.
 led to a significant decrease in cell viability, which was shown 
-free and FGF-containing growth medium 
 staining also verified that the control and the FGF
. In contrast, spheroids treated with 
dead, as shown in Figure 23.  
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3.2.3. Morphology: 
In some cell lines, treatment with rhFGF2 resulted in dramatic changes in cell shape and 
morphology (Figure 24). After 72 hours, untreated cells remained closely attached to each 
other and in an epitheloid shape, whereas FGF treatment le
more spherical morphology. One possible interpretation of this phenomenon is EMT 
(epithelial-mesenchymal-transition). This effect also appeared after treatment with EGF, and 
was reproducible at different treatment concentrations.
 
 
 
 
3.2.4. Migration: 
In view of the remarkable morphology change in some cell lines after FGF2 treatment, cells 
were investigated concerning 
an increased motility after treatment with FGF2. In contrast, FGFR1 inhibition
led to a dramatically decreased motility. For representative graphs showing the covered area 
(%) from the start point up to 70 hours after treatment, see Figure 25A. There was also a 
remarkable difference in migration velocity found. After 30.5 hours, the SPC111 and SPC212 
cells had already covered about the fourfold area than the P31 and P31 res1.2 cel
shown in Figure 25B. A representative series of pictures is also shown in Figure 25C.
 
Figure 24: 
Morphological  changes of M38K and SPC212 cells after treatment with FGF2
hours.  
 
d to a fibroblastoi
  
their ability to migrate by Platypus assay. All cell lines showed 
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As an alternative approach, the ability to transmigrate through a membrane containing 
pores of 8 µm in diameter was analyzed by a Transwel
accordance to those from the Platypus assay. 
stimulated by FGF2, whereas when the FGFR was
transmigrate was significantly reduced, even when recombin
Representative pictures and the data interpretation are shown in Figure 26 below.
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Figure 25: 
Migratory behavior of representative cell lines within 72 hours, described by the percentage of covered area in platypus 
assay (A). Covered area in mm
2
*100 after 24 hours (B). Micrographs of 
growth conditions after 24 and 48 hours, respectively (C).
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3.2.5. Invasion: 
Invasion through a layer of 
membrane was tested by transwell invasion assay
increase, whereas FGFR1 inhibition resulted in reduced invasion ability of all cell li
However, the effects were not as strong as in the migration assays 
significance only in p31 res1.2 cells 
 
 
 
 
 
 
 
 
 
Figure 26: 
Representative pictures of cell clones after 10 days. Cells were treated and allowed to transmigrate for 24 hours (A).
Analysis of the transwell migration assay (B).
 
SP
C1
11
0
50
100
150
200
in
v
as
io
n
 
(%
 
co
n
tr
o
l)
Figure 27: 
Evaluation of the transwell invasion assay. Cells were treated for 72 
hours. The transmigrated cells were allowed to form clones for 7 
days. 
 
 
 
 
 
 
 
 
collagen and subsequent transmigration through 
. Again, treatment with FGF2 le
and reached statistical 
(Figure 27). 
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3.3. Cell Signaling: 
 
To investigate the impact of exogenous FGF2 and the FGFR1 inhibitor PD166866 on FGFR
mediated downstream signaling, W
Analysis revealed that stimulation with FGF2 activates the Ras and the PI3K pathway. 
Phosphorylation of the downstream targets ERK
after treatment as shown in Figure 28A
after FGF was added. In contrast, FGF2 stimulation had no remar
STAT3 phosphorylation, it even seemed to act slightly inhibiting.
Otherwise, the FGFR1 tyrosine kinase inhibitor PD
of ERK and S6, even when additional FGF2 was added (Figure 
lines tested, for example in SPC111, P31 and P31res1.2, PD166866 was
drive STAT3 phosphorylation. 
unclear, but it may be the result of feedback loops or intracellular rescue mechanisms.
 
 
 
 
 
 
 
Figure 28: 
Western blot analysis of FGFR downstream targets from cell lysates after treatm
(A) and/or the FGFR1 inhibitor PD166866 for 24 hours (B). β
estern blots were performed.  
 and S6 were already detectable 15 minutes 
. The highest phosphorylation peak is reached 1 hour 
kable stimulating impact on 
 
166866 strongly inhibited phosphorylation 
28B). Surprisingly, in most cell 
 observed to strongly 
Why the JAK/STAT pathway is activated by PD166866
ent with FGF2 f
-actin was used as loading control. 
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3.4. Combination experiments: 
 
3.4.1. FGFR Inhibition & Chemotherapeutics: 
To investigate cell line sensitivity to cytostatics in vitro and monitor potentially enhanced 
efficacy in combination with FGF receptor inhibition, PD166866 and SU5402 were combined 
with commonly used chemotherapeutics. Both agents were applied at several 
concentrations as shown in Table 7 and MTT assays were performed to check alterations in 
cell proliferation. 
All in all, results showed remarkable differences in single drug sensitivity for the different 
drugs and cell lines. The IC50 values for each drug and cell line are listed in Table 20.  
 
Table 20: 
IC50 values of all used drugs after 72 hours treatment in 10% FCS. 
 
 
 
 
 
 
Again, as already observed in previous experiments (Table 19), SU5402 generally showed a 
weaker impact on MPM cell growth than PD166866, as shown in Figure 29. 
Looking at the IC50 values, 6 of 8 cell lines tested seemed to be quite resistant to cisplatin 
used as single drug. However, in combination with PD166866, in most cell lines increased 
efficacy was observed. We also observed that in some cases, those cell lines which are 
resistant to cisplatin showed a higher susceptibility to the FGFR1 inhibitor PD166866 than 
those which are more cisplatin sensitive. This effect was observed for example in the two 
biphasic cell lines SPC111 and SPC212 (Figure 29), and in the epitheloid P31 and its cisplatin-
resistant derivate, P31res1.2 cell line (Figure 30).  
Pemetrexed and gemcitabine, though they appeared to be strongly proliferation-inhibiting 
when used as single drug at very low doses, showed very weak or even antagonistic effects 
when combined with PD166866 in vitro (Figure 31A, B). 
Vinblastine and trabectedin led, especially in low concentrations, to increased effects when 
combined with PD166866 (Figure 31C, D). 
IC50 values Cisplatin Pemetrexed Trabectedin Gemcitabine Vinblastine 
SPC111 0.9 µM 0.65 µM 3,87 nM 0.2 nM 3.36 nM 
SPC212 >5 µM >100 µM 4.82 nM 2.49 nM 4.08 nM 
P31 >5 µM >100 µM 8.33 nM 0.5 nM 2.6 nM 
P31res1.2 >5 µM 1.1 µM 6.45 nM 0.77 nM 1.5 nM 
I2 2.51 µM - - - - 
M38K >5 µM - - - - 
VMC6 >5 µM - - - - 
VMC20 >5 µM - - - - 
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Figure 29: 
Dose-dependent survival curves of MPM cell lines treated with cisplatin and the small molecule inhibitors 
PD166866 (B) for 72 hours in medium containing 10% FCS evaluated by MTT assays.
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Figure 30: 
Enhanced effects of cisplatin and PD166866 in combination, compared to single agent treatment for 72 hours in medium 
containing 10% FCS. Viability was determined by MTT assay and means and SEM from 
Cisplatin was applied at a concentration of 5 µM and PD166866 at 10 µM. 
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Figure 31: 
Survival curves of selected cell lines treated with PD166866 in combination with pemetrexed 
vinblastine (C) and trabectedin (D) evaluated by MTT assay 72 hours after treatment in medium containing 10% FCS.
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 To better evaluate additive, synergistic or antagonistic effects
with different drugs, combination indice
software. In most cell lines, PD166866 inte
when combined with cisplatin or trabectedin
different drug concentrations are shown in Figure 32.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 32: 
Combination indices (CI values) of PD166866 in combination with trabectedin (A) or cisplatin (B), respectively, in 
selected MPM cell lines. Values between 0.9 and 1.1 are considered as 
values as antagonistic effects. 
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3.4.2. FGFR Inhibition & Radiation: 
FGF receptor inhibition was also combined with irradiation and MTT assays were performed 
to evaluate effects on cell growth. Most of the cell lines showed a dose dependent additive 
decrease of proliferation when irradiation was combined with different concentrations of 
PD166866 (Figure 33). Additionally, in two cell lines this effect was also obtained by 
transduction with the dnFGFR1 adenoviral construct as shown in Figure 34. 
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Figure 33: 
Viability of MPM cells treated with different concentrations of PD166866 with and without irradiation. The experiment was 
performed after setting 1: irradiation (2 Gy), drug treatment after 24 hours and 48 hours later evaluation via MTT assay. 
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Figure 34: 
Viability of MPM cells treated with the dnFGFr1 adenovirus or/and 
irradiation (2 Gy). Data was normalized to Ad-GFP-transduced control 
cells. The experiment was performed according to setting 2: drug 
treatment, followed by irradiation (2 Gy) 24 hours later and evaluation 
after total 72 hours. 
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4. DISCUSSION: 
 
Comprising about 12.7 million new cases and causing 7.6 million deaths per year (Jemal et al. 
2011) cancer is the second most common deadly disease in the modern world and still 
remains a major challenge for public health. During the last decades, extensive cancer 
research has led to exciting progress in understanding the nature and the background of 
cancer and its development, as well as many different and new approaches of cancer 
prevention, and anti-cancer therapy raising quality of life for patients. Thus, though 
nowadays many cancer types can be successfully prevented or cured, the prognosis for 
patients suffering from MPM remains dismal with a median survival of 9-12 months 
(Robinson, Musk et al. 2005). Since chemo- and radiotherapy is frequently inefficient and 
curative surgery is not possible in many cases, current therapeutic options are very limited 
and only show modest benefits. Consequently, the development of novel and more effective 
therapies for mesothelioma is urgently needed. Lately, the translation of molecularly 
targeted therapy approaches into clinical practice has become a very promising option in the 
fight against cancer. This strategy has already improved treatment of various malignancies, 
raising hopes also to shape up as an additional option in mesothelioma therapy.  
While inhibition of the epidermal growth factor receptor (EGFR) via specific tyrosine kinase 
inhibitors or antibodies has improved patient survival in several tumor types including non-
small cell lung cancer (NSCLC) harboring a mutated variant of the EGFR (gefitinib, erlotinib), 
colorectal (cetuximab) and breast cancer (lapatinib), clinical trials have shown only poor 
effects against MPM (Govindan et al. 2005; Garland et al. 2007). Vatalanib, which is a small-
molecule inhibitor that blocks all vascular endothelial growth factor tyrosine kinases (VEGFR) 
has also shown minor activity in mesothelioma treatment (van Meerbeeck et al. 2011). 
Bevacizumab, an antibody against VEGF, was given in addition to gemcitabine and 
carboplatin chemotherapy in a phase II trial but showed no benefit in terms of prolonged 
patient survival (Fennell, Gaudino et al. 2008).  The multi-targeted tyrosine kinase inhibitors 
sorafenib and sunitinib, which have useful activity in renal carcinoma and gastrointestinal 
stromal tumors, have been observed to be ineffective in MPM in clinical trials (Dubey et al. 
2010; Rudd 2010). A recent preclinical study showed that temsirolimus, an inhibitor of the 
mammalian target of rapamycin (mTOR), has anti-proliferative and pro-apoptotic effects 
against MPM cells in vitro as well as in mouse models and moreover synergizes with the 
chemotherapeutic agent cisplatin (Hoda et al. 2011). Currently, two clinical trials are ongoing 
to evaluate the role of mTOR inhibition in MPM patients (www.clinicaltrials.gov; Linda 
Garland, University of Arizona and Lee Krug, MSKCC NY). 
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Expression analysis: 
The FGF/FGFR axis plays a ubiquitous role in normal cell growth, differentiation and survival, 
essential for physiological processes such as embryonic development, angiogenesis and 
wound healing, but similar to the EGFR signaling system, has also been implicated in tumor 
formation. Recent studies have shown that the expression of components of the FGF 
signaling network is altered in multiple tumors, supports tumor formation in animal models 
and is frequently associated with poor prognosis and resistance to chemotherapy (Korc and 
Friesel 2009; Heinzle, Sutterluty et al. 2011; Wesche et al. 2011). However, FGFs and FGRs 
have not been systematically evaluated in mesothelioma so far. 
For this reason, we performed an expression analysis of the FGF/FGFR axis including all four 
receptors and their different isoforms and the 22 human ligands in nine mesothelioma cell 
lines including epitheloid and biphasic subtypes via conventional PCR, qRT-PCR and 
immunoflourescence. Selected members of the gene family were further analyzed in human 
tissue samples via immunohistochemistry. Our results showed a high expression of several 
members of the FGF family; especially FGF2 and FGF18 were found highly expressed in a 
high proportion of MPM cell lines as well as in tumor tissue. Immunohistochemistry also 
showed polarized tumor cells with stronger accumulation of FGF2 at the apical side, 
indicating secretion into the lumen. So far, the results of the immunohistochemical staining 
of 60 MPM tissue samples for FGF2 and FGF18 have not been completely evaluated and a 
correlation with histological subtypes and clinical data has yet to be made. FGF5 was also 
observed to be highly expressed in several MPM cell lines. Expression of FGF2 in 
mesothelioma has been already described (Kumar-Singh et al. 1999), but so far there are no 
reports on FGF18 in MPM available. However, FGF18 has been suggested to play a role in 
the malignancy of colon cancer and affects both the tumor cells and the microenvironment 
in a pro-tumorigenic and pro-metastatic way (Sonvilla et al. 2008). Expression of all four FGF 
receptors could be detected in all MPM cell lines. Generally, FGFR1 showed the highest 
expression level and was found overexpressed in eight of nine cell lines compared to a non-
malignant mesothelial control cell line. FGFR1 could also be detected in its activated form 
(pY653/654) via immunoflourescence in selected cell lines and by immunohistochemistry in 
human tumor samples.  FGFR4 was also found highly expressed in most cell lines tested, 
which is interesting because unlike FGF2, which binds and activates all four FGFRs, FGF18 
can only efficiently activate FGFR4 (and FGFR3IIIc), but not FGFR1 (Zhang et al. 2006). A quite 
similar expression pattern, characterized by a remarkably high expression of FGFR1 and 
FGFR4 as well as FGF2, FGF5 and FGF18, has been described in melanoma (Metzner et al. 
2011). In contrast, dominance of FGFR2 and FGFR3 expression has been recently reported in 
head and neck squamous cell carcinoma (HNSCC), whereas FGFR1 could be detected in only 
one out of nine cell lines tested (Marshall et al. 2011).  
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Overexpression of FGFR1 by gene amplification frequently occurs in breast cancer and is 
related to poor prognosis (Jacquemier et al. 1994; Letessier et al. 2006). Furthermore, 
overexpression of FGFR2, FGFR4, FGF3, FGF8 and FGF10 has also been described in subsets 
of human breast cancers (Penault-Llorca et al. 1995; Marsh et al. 1999; Naidu et al. 2001; 
Theodorou et al. 2004; Turner et al. 2010). In prostate cancer, FGFR1 and FGFR4 are also 
overexpressed (Sahadevan et al. 2007) and increased transcription levels of FGF1, FGF2, 
FGF6, FGF7, FGF8, and FGF9 have been found (Kwabi-Addo et al. 2004; Murphy et al. 2010). 
In approximately 20% of multiple myeloma patients, FGFR3 is overexpressed as a 
consequence of a translocation (Chesi et al. 1997). Elevated expression levels of FGF2 have 
been identified in body fluids of patients with cancers of colon, liver, bladder, head and neck, 
skin, lung, kidney, brain and soft tissue as well as in melanoma (Brunner et al. 1994; Nguyen 
et al. 1994; Nguyen et al. 1994; Nguyen et al. 1994). But also other FGFs, for instance FGF3, 
FGF4 and FGF8 have been found overexpressed in certain human cancers such as ovarian 
and esophagus carcinoma and Kaposi’s sarcoma (Kiuru-Kuhlefelt et al. 2000). 
Concerning lung cancer, frequent amplification of FGFR1 has been found in NSCLC as well as 
in small cell lung cancer (SCLC) (Voortman et al. 2010; Weiss et al. 2010).  In SCLC, high levels 
of serum FGF2 are associated with poor prognosis (Ruotsalainen et al. 2002). Furthermore, 
co-expression of distinct FGFs and FGFRs has been observed in NSCLC cell lines, suggesting 
involvement of an FGFR-dependent autocrine signaling pathway (Marek et al. 2009). 
Approximately 70% of bladder cancers harbor mutations in FGFR3 (Pandith et al. 2010). An 
activating point mutation of FGFR3 was also found in cervix carcinoma (Cappellen et al. 
1999), mutations in FGFR2 have been identified in endometrial carcinomas (Pollock et al. 
2007) and a constitutively activated form of FGFR4 has been described in pituitary tumors 
(Ezzat et al. 2002). Mutated forms of FGF receptors have also been reported in brain, head 
and neck, stomach and colon cancer (Jang et al. 2001; Rand et al. 2005; Chou et al. 2009), as 
well as in rhabdomyosarcoma (Taylor et al. 2009) and small cell lymphocytic lymphoma (Xiao 
et al. 1998). 
Taken together, our expression data, demonstrate that certain members of the FGF/FGFR 
family are highly expressed and activated in MPM cells, in the light of the available literature 
indicating an involvement of FGF signaling in development and progression also for this 
tumor type. 
 
Stimulation of MPM cells with FGF2: 
Since FGF2 is a ubiquitous cellular mitogen and was shown to be highly upregulated in 
multiple tumor types including, according to our data, mesothelioma, its oncogenic effects 
on mesothelioma cell lines was further investigated.  
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In our study, mesothelioma cell lines were stimulated with recombinant human FGF2 and 
the impact on two- and three-dimensional cell growth and proliferation, migration, invasion 
as well as on downstream signaling pathways was investigated.  
MTT- and clonogenic assays showed an increase in cell growth of about 15-20% that rises 
with lower serum concentrations. Considering three dimensional growth, nine out of ten 
mesothelioma cell lines were able to form viable spheroids when cultured in serum free 
medium containing adjuvants including FGF2. When FGF2 was omitted, only a moderate 
decrease of cell proliferation to approximately 80% compared to normal conditions was 
observed. Spheroid number and size were also in most cell lines not significantly affected. 
These findings could be explained by overexpression of FGF2 and suggest supply of FGF2 in 
an autocrine manner. Furthermore, in two cell lines, we observed dramatic changes in cell 
morphology, from an initially epitheloid to a much more spherical and fibroblast-like shape, 
which may indicate growth factor-induced EMT, leading to an increased ability to migrate. 
Recently, FGF2 has been described to play a role in EMT of corneal endothelial cells which is 
related to corneal fibrosis (Lee et al. 2011). Both cell lines are established from tumors of the 
biphasic histotype, which is interesting and clinically relevant because sarcomatoid (and also 
biphasic) pleural mesothelioma has a worse prognosis compared to epitheloid MPM 
(Chirieac and Corson 2009). The same effect was also observed after treatment with EGF and 
in both cases, became more pronounced with rising growth factor concentrations. 
Migration assays (Platypus and Transwell assay) showed significantly increased motility in 
most cell lines tested, and also for the ability to transmigrate through a porous membrane. 
In addition, remarkable differences in migration velocity between the different cell lines 
were observed, showing the general trend that those cell lines established from a biphasic 
MPM (SPC111, SPC212) migrate much faster than those established from tumors of 
epitheloid histotype. This would be in agreement with the higher aggressiveness of the 
sarcomatoid and biphasic histotypes. In agreement with our data, FGF2 has also been shown 
to enhance growth and migration potential in melanoma cells (Metzner et al. 2011).  
With regard to invasion through a collagen-coated transwell membrane, we also observed 
an increase of approximately 20-50% in three out of four cell lines after treatment with 
FGF2, but the increase was by far not as strong as for transmigration, where values were 
enhanced between 150% and even nearly 500%. A possible explanation for the minor effects 
when membranes were coated with collagen may be that the invasion process, which 
requires collagen-degradation, is less dependent on FGFR-mediated signaling than two-
dimensional migration or transmigration through a pore.  
Additionally, we looked into more detail concerning FGFR-mediated downstream signaling 
pathways. Cells were treated with FGF2 for different time periods ranging from 15 minutes 
to 24 hours and Western blot analysis was performed. Results showed high levels of 
phosphorylated ERK and S6 already after 15 minutes, reaching the peak at about 1 hour. 
After 24 hours, phosphorylation levels were still increased in comparison to the endogenous 
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phosphorylation status, whereas total protein levels remained almost unchanged. In 
contrast, phospho-STAT3 was unaffected and seemed even to be reduced after treatment 
with FGF2.  
Consequently, in MPM cells, FGF2 leads to activation of the MAPK as well as the PI3K/AKT 
pathway, both driving cell proliferation, migration and survival, but unexpectedly has rather 
a suppressive influence on the STAT3 pathway, which is also involved in cell growth, survival 
angiogenesis (Klampfer 2006). However STAT3 has also been described as tumor suppressor, 
for instance in HCC cells lacking p14ARF or p19ARF in mouse models (Schneller et al. 2011), 
indicating the existence of a pro- as well as an antioncogenic role of STAT3 in liver cancer, 
directly depending on p14ARF/p19ARF expression (Calvisi 2011). In mesothelioma, as well as in 
NSCLC, STAT3 is thought to be involved in tumor motility, invasion and metastasis acting in 
its cytoplasmic, unphosphorylated and inactive form via a non-transcriptional pathway 
(Achcar Rde et al. 2007). 
All in all, our results show that stimulation with FGF2 leads to increased proliferation, 
migration and invasion as well as to activation of downstream pathways which are involved 
in tumor progression, such as the MAPK and PI3K/AKT pathway, in MPM cells. 
 
Inhibition of FGFRs in MPM cells: 
In vitro experiments already showed that inhibiting of FGF-mediated signals led to reduced 
cell growth and migration in various tumor types, including multiple myeloma, glioblastoma, 
bladder, lung and colon cancer by induction of apoptosis as well as inhibition of cell 
migration (Allerstorfer et al. 2008; Fischer et al. 2008; Qing et al. 2009; Sonvilla et al. 2010).  
Currently, for clinical applications, there are two common strategies for intervention at the 
protein level of receptor tyrosine kinases such as FGFRs. Small molecule tyrosine kinase 
inhibitors targeting FGF receptors comprise a promising approach for targeted cancer 
therapy and several agents are currently in the early phase of clinical trials. Due to the high 
homology of the kinase domains, it is very difficult for these inhibitors to obtain FGFR 
subtype specificity. Furthermore, related growth factor receptors such as VEGFR, EGFR and 
PDGFR are also affected. For instance, sunitinib, a multikinase inhibitor, has useful activity in 
renal carcinoma and gastrointestinal stromal tumors (Motzer et al. 2006; Motzer et al. 
2006). BGJ398 and AZD4547 are two FGFR specific small molecule inhibitors developed by 
Novartis and Astra Zeneca, which are currently tested in clinical studies with advanced solid 
tumors that have a FGFR1 or FGFR2 amplification or a mutated FGFR3 and in combination 
therapy for a subset of breast cancer, respectively (Heinzle, Sutterluty et al. 2011). The 
second approach, blocking antibodies targeting specific FGFR subtypes and FGF ligand traps 
provide a more specific inhibition of FGF signaling with fewer side effects. For bladder cancer 
and multiple myeloma, antibodies targeting FGFR3 have been reported to inhibit tumor cell 
growth in vitro and in vivo (Qing, Du et al. 2009). In mouse models, monoclonal antibodies 
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against FGF8 have shown some efficacy against breast and prostate cancer (Shimada et al. 
2005; Maruyama-Takahashi et al. 2008). Thalidomide inhibited FGF2-induced angiogenesis 
and led to benefits in patients suffering from renal and prostate cancer (Eisen et al. 2000; 
Figg et al. 2001).  
In reference to our observations that FGF2 may also play a mitogenic role in MPM, we next 
focused on inhibition of FGFR signaling, more precisely, of FGFR1, which is overexpressed in 
eight out of nine cell lines. In our study, we used the specific small molecule inhibitors 
SU5402 and PD166866, as well as an adenoviral construct expressing a dominant-negative 
variant of the FGFR1, to monitor the impact of blocking FGFR1-mediated signaling on 
mesothelioma cell lines in vitro. SU5402 and the FGFR/VEGFR inhibitor PD173074 have 
already proven effective against multiple myeloma cell lines through inhibition of FGFR3 and 
PD173074 has also shown to have useful in vitro activity in a subset of endometrial cancers 
(Grand et al. 2004; Byron et al. 2008; Meyer et al. 2008). 
In general, proliferation assays showed cell line specific differences in response to the small-
molecule inhibitors, but both of them were able to significantly reduce cell proliferation. 
Interestingly, for SU5402, which is considered to target multiple kinases, we observed only a 
weak effect in comparison to the FGFR1 specific PD166866, which reduced cell viability to 
approximately 10-40% when applied at a concentration of 10 µM in clonogenic assays.  A 
significant decrease of cell viability was also reached by the dnFGFR1 adenovirus, but some 
cell lines also showed high sensitivity to the GFP control virus, indicating toxic effects of the 
viral transduction itself, although optimal viral MOI have been determined before. 
Consequently, the effect of the dominant-negative FGFR1 with a reduction to 40-80% is 
generally weaker. In three-dimensional growth, PD166866 significantly reduced spheroid 
number, size and cell viability in all cell lines tested, compared to the control cells as well as 
to those in FGF-free growth conditions. In the context of our data from FGF2 stimulation, 
these findings lead to the conclusion that three-dimensional MPM cell growth is dependent 
on FGFR-mediated signaling, because when FGFR1 is blocked, cells are no longer able to 
grow in spheroids even when FGFs are present in the growth medium. However, the cells 
are not addicted to additional FGFs in the medium and able to produce FGFs in an autocrine 
way. In this context, suramin, an inhibitor of extracellular growth factors including FGFRs by 
mimicking heparin, which has already shown improvement in bladder, kidney and prostate 
cancers (Beenken and Mohammadi 2009) has also been described to inhibit growth of 
malignant mesothelioma in vitro and in vivo (Cook et al. 2003).  
Considering motility, PD166866 proved to be a potent inhibitor that led in all MPM cells 
tested by platypus assay to a significant reduction of cell migration of at least 50-75%. This 
trend that FGFR blocking inhibits migration was also supported by transwell assays, although 
in these experiments effects were more moderate. In general, transmigration and invasion 
was more affected by PD166866 in epitheloid cell lines (40-60% reduction) than in biphasic 
(20-30% reduction).  
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In contrast to FGF2, which resulted in an enhancement of phosphorylation of ERK and S6, 
PD166866 consequently reduced the activation of these downstream targets compared to 
endogenous levels and total protein. Surprisingly, FGFR inhibition led to partly highly 
increased levels of phospho-STAT3, indicating the existence of feedback-loops or alternative 
rescue mechanisms to drive cell growth. This effect of PD166866 on STAT3 phosphorylation 
seems to be mesothelioma cell specific as it was not observed in a recent study on 
melanoma cells (Metzner, Bedeir et al. 2011). 
In summary, these data clearly show that blocking FGFR-mediated signaling, either via small-
molecule inhibitors or genetic constructs, dramatically affects MPM cells by significantly 
reducing cell growth, motility and survival and changing downstream signaling. 
 
Targeting the FGF/FGFR axis in mesothelioma therapy: 
Comprising one of the major drivers of malignant growth and metastasis in multiple tumors 
(Heinzle, Sutterluty et al. 2011; Wesche, Haglund et al. 2011) the FGF/FGFR axis offers new, 
exciting and powerful opportunities for targeted cancer therapy in several malignancies, 
including mesothelioma. However, FGF signaling is also centrally involved in various 
regulatory networks and responsible for a variety of essential physiological functions not 
only in embryonic development, but also in the adult organism. Consequently, investigating 
new therapeutic options by blocking FGF signals is also coupled to a high risk of potential 
side effects for the patient. Thus, the most challenging question is to find strategies of well 
balanced target inhibition combined with conventional chemo-and radiotherapy with 
minimal side effects and optimal outcome for each tumor type. 
To evaluate the FGF/FGFR axis as potential target in anti-mesothelioma therapy, we 
analyzed the effect of FGFR inhibition by small molecules in the context of combination with 
classical chemotherapeutics, for instance cisplatin and pemetrexed, the current standard 
therapy in mesothelioma treatment, gemcitabine and vinblastine, currently discussed as 
anti-mesothelioma therapy (Muers et al. 2008). Additionally the effects of trabectedin, a 
novel compound currently used in soft tissue sarcoma (Gajdos and Elias 2011) were 
analyzed. 
In case of cisplatin, vinblastine and trabectedin, inhibition of FGF signals could enhance the 
overall effectiveness of treatment. After calculating the combination indices (CI values), we 
observed in most cell lines tested a synergism between PD166866 and cisplatin or 
trabectedin, resulting in a remarkable decrease of MPM cell viability. However, looking at 
vinblastine, mainly additive effects were obtained in proliferation assays.  
In contrast, FGFR inhibition combined with gemcitabine or pemetrexed used as single agents 
resulted in generally weak and partly antagonistic effects in MPM cell growth. Gemcitabine 
have been shown to be active in multiple tumors including mesothelioma in vitro.  
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However, in patients the response rated to gemcitabine used as single agent are very poor, 
but it is commonly used in combination with cisplatin or carboplatin, showing synergistic 
effects and good response (Kindler and van Meerbeeck 2002).  Pemetrexed, used as single 
agent or in combination with other chemotherapeutics, has also demonstrated activity in 
various tumor types. In mesothelioma, pemetrexed combined with cisplatin has been 
approved as standard therapy (Rollins and Lindley 2005). 
Additionally, we observed that the cisplatin-resistant P31res1.2 cell line shows higher 
susceptibility to PD166866 (IC50: 11.9 µM) compared to its parental cell line P31 with an IC50 
value of 14.5 µM. This is also true for other cell lines, for example the biphasic cell lines 
SPC111 and SPC212. The highly cisplatin-susceptible SPC111 cell line with an IC50 value of 0.9 
µM seems to be insensitive to FGFR inhibitors, showing IC50 values of 22.9 µM for PD166866 
and over 25 µM, our maximum concentration, for SU5402. In contrast, in SPC212 cells, which 
are quite resistant to cisplatin with the maximum dose of 5 µM reaching only 35-40% growth 
reduction, the IC50 value for the specific FGFR1 inhibitor PD166866 lies at 9.2 µM. This is 
interesting, because an inverse relationship of cisplatin and targeted therapy response was 
also recently described in a study focusing on mTOR inhibition via temsirolimus in MPM cell 
models (Hoda, Mohamed et al. 2011). The general trend that MPM cells showing resistance 
to conventional chemotherapy respond better to targeted treatment is very promising and 
also clinically relevant.  
Furthermore, we also tested FGF signals in combination with radiotherapy. FGFR1 inhibition 
as well as treatment with recombinant FGF2 was combined with irradiation (2 Gy) in three 
different experimental settings. Again, in most cell lines a reduction of cell viability was 
observed when FGFR1 were inhibited by PD166866 and also the adenoviral construct. 
Radiosensitization of cells by blocking RTK-mediated survival signals has been previously 
demonstrated for EGFR and recently, the EGFR inhibitor cetuximab has been shown to 
increase long-term survival of patients suffering from head and neck cancer when applied in 
combination with radiotherapy (Bonner et al. 2010). Treatment with recombinant FGF2, 
however, had no remarkable effects on susceptibility to irradiation in MPM cells. 
 
Conclusion and outlook: 
Due to the rising incidence, which is expected to continue in the next decades, and the poor 
clinical response, malignant pleural mesothelioma has become more and more clinically and 
epidemiologically significant and relevant. Thus, further research to understand this 
devastating malignancy and to find new and more effective treatment strategies is still an 
important goal, where targeted therapies may play a major role. 
In our study we showed that certain FGFs as well as FGFRs are overexpressed and activated 
in MPM cells. We also proved FGF signals as important mediators required for two- and 
three-dimensional MPM cell growth, survival, migration and invasion. Furthermore, our data 
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indicate to some extent synergistic improvement of chemo-and radiotherapy when 
combined with FGFR inhibition. 
Since our in vitro data provide strong evidence that FGF signaling are important factors in 
development and progression of MPM, we are planning to continue our study by performing 
in vivo experiments in mouse models to further investigate the FGF/FGFR axis as potential 
therapy target in human malignant mesothelioma. Now and in the future, targeted therapies 
and their personalized application, not only for FGFs, will remain a hot topic in cancer 
research and a lot of effort in clinical trials combined with high quality translational research 
will be needed to finally find optimal therapeutic applications for each patient and cancer 
type. 
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5. APPENDIX: 
 
5.1. List of abbreviations: 
 
APS - Ammonium persulfate 
ATP - Adenosine triphosphate 
BSA - Bovine serum albumin 
CRP - C-reactive protein 
CV - Crystal violet 
CT - Computed tomography 
DAB - 3,3'-diaminobenzidine 
DAPI - 4',6-diamidino-2-phenylindole 
DMEM - Dulbecco’s Modified Eagle Medium 
DMSO - Dimethylsulfoxid 
DNA - Deoxyribonucleic acid 
dNTP - Deoxyribonucleotide triphosphate 
ECM - Extracellular matrix 
EDTA - Ethylendiaminetetraacetic acid 
EGF - Epithelial growth factor 
EGFR - Epithelial growth factor receptor 
EMT - Epithelial-mesenchymal transition  
EPP - Extrapleural pneumonectomy 
ERK - Extracellular signalregulated kinase 
FCS - Fetal calf serum 
FGF - Fibroblast growth factor 
FGF-BP - FGF binding protein 
FGFR - Fibroblast growth factor receptor 
FHF - Fibroblast homology factor 
FRS2 - Fibroblast Growth Factor Receptor Substrate 2 
GAPDH - Glyceraldehyde 3-phosphate dehydrogenase 
GFP/EGFP - Green fluorescent protein/Enhanced green fluorescent protein 
HEPES - 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
HLGAG - Heparin-like glycosaminoglycan 
HNSCC – head and neck squamous cell cancer 
HPV - Human papilloma virus 
HRP - Horseradish peroxidaase 
IGF - Insulin-like growth factor 
MAPK - Mitogen activated protein kinase 
MEME - Minimum Essential Eagle Medium 
MET - Mesenchymal-epithelial transition 
MM – Multiple myeloma 
MOI - Multiplicity of infection 
MPM - Malignant pleural pesothelioma 
MRT - Magnetic resonance tomography 
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mTOR - mammalian target of rapamycin 
MTT – Dimethyl thiazolyl diphenyl tetrazolium salt 
N-CAM - Neural cell adhesion molecule 
NSCLC - Non-small cell lung cancer 
P/S - Penecilin/Streptomycin 
P/D - Pleurectomy/Decortication 
PBS - Phophate buffered saline 
PDGF - Platelet-derived growth factor 
PDGFR - Platelet-derived growth factor receptor 
PET - Positron emission tomography 
PFA - Paraformaldehyde 
PI - Propidium iodide 
PI3K - Phosphotidyl-inositol-3-OH kinase 
PKC - Protein kinase C 
PLC - Phospholipase C 
PVDF - Polyvinylidene fluoride 
qRT-PCR - quantitative real-time polymerase chain reaction 
RMS - Rhabdomyosarcoma 
RNA - Ribonucleic acid 
RPMI - Roswell Park Memorial Institute 
RT-PCR - Reverse transcription polymerase chain reaction 
RTK - Receptor tyrosine kinase 
SCLC – Small cell lung cancer 
SCM - Stem cell medium 
SDS-PAGE - Sodium dodecyl sulfate polyacrylamide gel electrophoresis 
SNP - Single nucleotide polymorphism  
SRMP - serum mesothelin-related protein  
STAT - Signal transducer and activator of transcription 
SV40 - Simian Virus 40 
TBE - Tris/Borate/EDTA 
TBS - Tris buffered saline 
TEMED - N,N,N´,N´-tetramethylethylenediam 
VATS - Video-assisted throacoscopic surgery 
VEGFA - Vascular endothelial growth factor A 
VEGFR - Vascular endothelial growth factor receptor 
VMC - Vienna mesothelioma cell 
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